Integrin specificity as a novel strategy for enhancing transplanted stem cell survival and tissue repair in vivo by Clark, Amy Yee lae
INTEGRIN SPECIFICITY AS A NOVEL STRATEGY FOR 
ENHANCING TRANSPLANTED STEM CELL SURVIVAL AND 











A Dissertation  
Presented to  













In Partial Fulfillment 
Of the Requirements for the Degree 















Copyright © 2016 Amy Clark  
INTEGRIN SPECIFICITY AS A NOVEL STRATEGY FOR 
ENHANCING TRANSPLANTED STEM CELL SURVIVAL AND 




























Dr. Andrés J García, Advisor 
George W. Woodruff School of 
Mechanical Engineering  
Georgia Institute of Technology 
 
Dr. Thomas Barker  
Wallace H. Coulter Department of 
Biomedical Engineering 
Georgia Institute of Technology and 
Emory University 
 
Dr. Edward Botchwey 
Wallace H. Coulter Department of 
Biomedical Engineering 
Georgia Institute of Technology and 
Emory University 
Dr. Robert Guldberg  
George W. Woodruff School of 
Mechanical Engineering  
Georgia Institute of Technology 
 
Dr. Todd McDevitt 
Roddenberry Center for Stem Cell 
Biology & Medicine 
Department of Bioengineering & 
Therapeutic Sciences 
Gladstone Institutes and University of 












































I would first and foremost like to thank my parents for their infinite love and 
support. Thank you for providing me with everything and anything I ever needed or wanted 
and setting me up for success. Thank you for working so hard to give us the best life and 
for all of the things that you did for me, Alan and Jenny that I never knew about. Thank 
you for supporting me and my decisions, even if you didn’t quite agree and for loving me 
unconditionally. You are my inspiration and my role models. Dad, your resourcefulness 
and unwavering determination to fix or make everything yourself has empowered my 
creativity and out-of-the-box thinking. As the original engineer, you are the first and most 
influential inspiration I had for pursuing engineering. Mom, thank you for always being 
there for us growing up. Your strength, selflessness, and compassion inspire me to be a 
better wife, sister, daughter, and (way in the future) mother every day. I love you two and 
am so grateful for everything you have done for me. No amount of thank you’s would ever 
be enough.  
Alan, Jenny, and Nicole - Thank you for being role models for me and for 
supporting and believing in me, and for bringing Tyler, Kaelyn, Landon and Hudson into 
our lives. Thank you for helping me settle in to Atlanta when I first got here. Alan, thanks 
for making fun of me when I was 5 for singing my “Mr. Sun” song wrong– you saved me 
from pursuing a singing career, but inspired me to pursue biomedical engineering by being 
the smartest, most compassionate doctor I know. Jenny, thank you for being like a mom to 
me, in addition to the best sister in the world. Your strength and love for Tyler and KK 





To my husband, best friend, #1 fan, motivator, and doggy daddy. I would not have 
finished this PhD so sane and humble and with moderate to high levels of stress (which is 
pretty good for a PhD) without you by my side these past 6 years. You were my rock, and 
my dinner provider, and my laundry doer when 14 hour days would turn my brain to mush. 
Thank you for coming with me to lab in the middle of the night and for always trying to 
help in any way that you could. I loved that you were so interested in what I did, and would 
continue to ask me to update you on my project’s progress even though the last thing I 
wanted to do when I got home was talk more science. This PhD is as much yours as it is 
mine, and I am so grateful I had you by my side the whole way through. I do have to also 
thank my PhD, though, because it brought me to Atlanta, and brought me to you. So many 
of our life’s milestones are entwined with my time at tech, I can’t help but look back fondly 
at everything, even the most stressful, difficult times in my PhD, but I am so excited to 
start a new journey with you. Thank you to Cooper, our dog and the light of our lives, for 
loving unconditionally and whole heartedly, especially on the worst of days. 
Thank you to my new family, the Clark/Stearn team for welcoming me with open 
and loving arms. Kirsten, Andy, Lincoln, and nephew-to-be, I’m so glad to have you in 
Atlanta. Karn and Phil, it’s your turn to make a move now! Thank you always being so 
supportive and interested in what I do. 
I would like to thank my 8th grade science teacher, Mr. Lawson, at Adams Middle 
School for making science fun and inspiring, and giving me the nickname, “Dr. Cheng.” I 
didn’t quite become Dr. Cheng, but Dr. Clark has a nice ring to it. I would also like to 




the first PhD I ever really met. Most of us wondered what he was doing teaching high 
school math, but you could tell he really loved what he did.  
To my thesis advisor, Andrés García. I feel very, very fortunate to have had the 
opportunity to work in your lab. I honestly don’t know why you took a chance with me. I 
didn’t know anything about cells or how to pipette when I first started. I just remember 
your booming voice and corny jokes at the BioE orientation day, and I knew I wanted to 
join your lab. You have been an unforgettable mentor, teacher, cheerleader, advocate, 
therapist, and friend. Thank you for everything you have done for me and the lab, for 
always having an open door, for talking us off ledges, for providing “perspective”, and for 
always having our best interests in mind. You have always valued our opinion on the 
direction of our projects and how to make the lab better. Thank you for pushing us and 
always expecting the best from us on this “bleeding edge of science.” 
Thank you to my committee members for their encouragement, guidance and 
feedback – Dr. Tom Barker for all your knowledge on ECM and what “integrin-specificity” 
really means. Dr. Ed Botchwey, thank you for your insight into modulating the immune 
system and for sharing your lab space and equipment. Thank you Dr. Todd McDevitt for 
your expertise into the world of stem cells, for making an effort to still attend updates and 
meetings in person all the way from San Fran, and especially for suggesting I convince 
Andrés to put me on the Stem Cell IGERT when I was interviewing for labs, because 
without that funding, I don’t think I would be where I am today. Thank you Bob Guldberg, 
for not only keeping IBB great, but also for your input on biomaterials and bone, and all of 
the bone-related expertise and technical know-how that your lab provides, and for the lair 




To the PRL vets and staff – Dr. Laura, Dr. Richard, Kim, Altair, Ogeda, Andrea, 
Brittany, Josh – thank you for always having a smile and a most welcoming hello ready 
every time I saw each of you. Thank you for keeping the PRL in tip top shape and always 
going above and beyond to make sure that our research went as smooth as possible. I most 
definitely could not have done this without y’all.  
To the Garcia lab, thank you for humoring me when I would get into my 
organizational, throw everything out, move everything around moods. I hope I helped make 
things easier for you, even if I may have made some things more difficult. A special thanks 
to Jose Garcia and Chris Johnson, who were willing to come in for surgery on a Saturday 
for me, but instead, spent a Friday night with me in the PRL. Jose, with our projects so 
similar, we’ve shared many a frustration over GFOGER and the defect and MSC and the 
struggle on what to do with your life- thank you for always being willing and ready to help 
or listen. Chris Johnson, thank you for easing up on the negative nanciness and always 
pointing out my RBF, and for being our resident MD and my climbing buddy. Devon 
Headen, D-von, thank you for being our fixer and for your don’t-beat-around-the-bush 
attitude. Efrain – thank you for always trying to round everyone up to do fun things, and 
keeping the lab like a party with all of your music. Charu Kumar, thank you for everything 
you’ve already done for the lab. I know I’ll be leaving the lab in good hands. 
Dave Dumbauld, you were so friendly and welcoming to me when I was just a little, 
scared 1st year – so out of character for an Ohio State fan! Ed Phelps, the PEG-mal pioneer, 
thank you for being a role model, even though I was terrified of you, and for making me 
remember how much I love rock climbing, and for pushing me to be a better climber. Asha 




and for leading the way in GFOGER, and for lighting up the room with your laugh. Ted 
Lee – you are one of a kind and unforgettable. Thank you for your words of wisdom, and 
for always rallying the troops. Your stress-free approach to research was something I 
envied and tried to copy. Stacie Gutowski, thank you for all of your delicious baked goodies 
and always being prepared with anything anyone might ever need for any situation. Rachel 
Sy, you were the original lab organizer and always reminded us when we were being slobs. 
Ram Selvam, thank you for sharing your bench with me from day 1. Apoorva Salimath, I 
will always remember those nights we stayed up together all night working on our 
biomaterials proposals. I am grateful to have had such a good friend by my side (literally 
and figuratively) since the beginning of grad school. Nduka Enemchukwu, you are one of 
the nicest people I have ever met and will fondly remember the philosophical talks in the 
TC room. Ankur Singh, you always brought delicious tandoori chicken and are an 
inspirational scientist.  
To the Guldburglars, thank you for sharing all of your things and space with us 
Garcia folk. Special thanks to Albert Cheng, my long, lost brother, and Hazel Stevens for 
helping me in my IHC time of need. And special thanks to Hazel for always putting up 
with Garcia lab shenanigans. Thank you to Angela Lin, for her expertise on all things 
microCT and biomechanics related, and for helping/not judging when we would lose things 
in the vivaCT.  
To the IBB staff, thank you for keeping everything running in tip top shape. Special 
thanks to Allen Echols, for always being so friendly and quick to help. Laura Paige, you 
honor Chris Ruffin’s memory well, and have made the BioE program better each year. 




attitude. And to Nadia Boguslavsky, Dalia Arafat, Aqua Asberry, Andrew Shaw, and 
Xingping Huang (at Emory) for being so helpful and on top of their cores. 
To the friends that I have made during my time at GT, thank you for the happy 
hours, and the beer festivals, and the lunch outings, and potlucks, and wonderful memories. 
The PhD is as much an emotional and personal challenge as it is technical and intellectual, 
and without you all by myside to vent, philosophize, laugh with, or let loose, this would 
not have been an easy, enjoyable ride as it was with y’all in my life. 
And lastly, I would like to dedicate this thesis to the memory of my great aunt 
Margaret, whose recent and unexpected passing was just too soon.  
 
Research reported in this publication was supported in part by the Office of the 
Director, National Institutes of Health under Award Numbers S10OD016264, R01 
AR062368, R01 AR062920, and Cell and Tissue Engineering Training Grant T32 
GM008433. This research project was supported in part by National Science Foundation 
IGERT for Stem Cell Manufacturing DGE 0965945 and the Viral Vector Core of the 





TABLE OF CONTENTS 
 
ACKNOWLEDGEMENTS ............................................................................................... iv 
LIST OF TABLES ............................................................................................................ xii 
LIST OF FIGURES ......................................................................................................... xiii 
LIST OF ABBREVIATIONS .......................................................................................... xvi 
SUMMARY ................................................................................................................... xviii 
CHAPTER 1: SPECIFIC AIMS ......................................................................................... 1 
SPECIFIC AIM 1 ............................................................................................................ 2 
SPECIFIC AIM 2 ............................................................................................................ 3 
SPECIFIC AIM 3 ............................................................................................................ 4 
SIGNIFICANCE ............................................................................................................. 5 
CHAPTER 2: LITERATURE REVIEW ............................................................................ 6 
ENGINEERING THE MATRIX MICROENVIRONMENT FOR CELL DELIVERY 
AND ENGRAFTMENT FOR BONe REPAIR  ............................................................. 6 
BIOLUMINESCENT IMAGING ................................................................................. 20 
CHAPTER 3: ENGINEERING AN INTEGRIN-SPECIFIC CELL 
MICROENVIRONMENT ................................................................................................ 22 
ABSTRACT .................................................................................................................. 22 
INTRODUCTION ......................................................................................................... 24 
METHODS.................................................................................................................... 27 
RESULTS...................................................................................................................... 33 
DISCUSSION ............................................................................................................... 44 
CHAPTER 4: THE ABILITY OF INTEGRIN-SPECIFIC HYDROGELS TO 
PROMOTE HMSC SURVIVAL AND BONE REPAIR IN VIVO ................................. 48 
ABSTRACT .................................................................................................................. 48 
INTRODUCTION ......................................................................................................... 50 
METHODS.................................................................................................................... 53 
RESULTS...................................................................................................................... 59 
DISCUSSION ............................................................................................................... 73 
CHAPTER 5: THE EFFECT OF INTEGRIN-SPECIFIC HYDROGELS AND HMSC 
ON THE REPAIR ENVIRONMENT IN VIVO .............................................................. 82 
ABSTRACT .................................................................................................................. 82 






DISCUSSION ............................................................................................................. 110 
CHAPTER 6: FUTURE CONSIDERATIONS .............................................................. 116 
APPENDIX ..................................................................................................................... 119 
KINETICS OF TIME TO MAXIMUM SIGNAL FOR BIOLUMINESCENT 
IMAGING ................................................................................................................... 119 
PUBLICATIONS ........................................................................................................ 120 
Well-defined Poly(lactic acids) Containing Poly(ethylene glycol) Side-chains. 
Macromolecules. ...................................................................................................... 120 
Bone regeneration using an alpha 2 beta 1 integrin-specific hydrogel as a BMP-2 
delivery vehicle. Biomaterials. ................................................................................ 128 
Microphysical space of a liver sinusoid device enables simplified long-term 
maintenance of chimeric mouse-expanded human hepatocytes. Biomedical 
Microdevices. .......................................................................................................... 137 
Integrin-specific hydrogels functionalized with VEGF for vascularization and bone 
regeneration of critical-size bone defects. Journal of Biomedical Materials Research 
Part A. ...................................................................................................................... 147 
Human Mesenchymal Stem Cell Behavior on Segmented Polyurethanes Prepared 
with Osteogenic Chain Extenders. Journal of Materials Science: Materials in 
Medicine. ................................................................................................................. 159 
Tobacco Mosaic Virus Functionalized Alginate Hydrogel Scaffolds for Bone 
Regeneration in Rats with Cranial Defect. ACS Biomaterials Science and 
Engineering. ............................................................................................................. 170 





LIST OF TABLES 
 
Table 1. Peptide hydrogel components. ........................................................................... 28 
Table 2. Mesh size calculations for a 4.5% (w/v) PEG hydrogel with 1 mM ligand....... 35 
Table 3. Gene targets for qPCR microarray. .................................................................... 88 
Table 4. Secreted cytokine levels of hMSC encapsulated in ligand-functionalized 






LIST OF FIGURES  
 
Figure 1. Schematic of cell delivery vehicle performance in vivo over time. .................... 9 
Figure 2. Schematic of functionalized hydrogel preparation. .......................................... 12 
Figure 3. Protease-degradable PEG hydrogel reaction scheme. ...................................... 26 
Figure 4. Ligand tethering efficiency and material properties. ........................................ 34 
Figure 5. Rheology of varying weight percent hydrogels. ............................................... 35 
Figure 6. Integrin-specificity of ligand-functionalized hydrogels. .................................. 36 
Figure 7. Viability and spreading of encapsulated hMSC. .............................................. 38 
Figure 8. Mutated, non-adhesive peptide control for GFOGER does not support cell 
adhesion. ........................................................................................................................... 39 
Figure 9. GAOGER does not support spreading of encapsulated hMSC. ....................... 39 
Figure 10. Western blot for FAK phosphorylation. ......................................................... 40 
Figure 11. Encapsulated cell number in ligand-functionalized hydrogels. ...................... 41 
Figure 12. Proliferation of encapsulated hMSC in ligand-functionalized hydrogels. ..... 42 
Figure 13. Osteogenic differentiation of encapsulated hMSC. ........................................ 43 
Figure 14. Murine radial segmental defect. ..................................................................... 56 
Figure 15. Representative 3-D microCT reconstruction of segmental defect at day 3. 
Dashed lines show schematic of bone volume quantification. ......................................... 58 
Figure 16. Schematic of luciferase reaction for bioluminescent cell tracking. ................ 59 
Figure 17. hMSCFLuc exhibit normal growth and differentiation capacities. ................... 61 
Figure 18. Effect of genetically modified hMSC on bone repair..................................... 63 
Figure 19. Effect of PEG weight percent and hMSC delivery on bone repair. ............... 64 




Figure 21. Effect of cell dose on bone repair. .................................................................. 65 
Figure 22. Effect of ligand density on bone repair. ......................................................... 66 
Figure 23. α2β1-specific GFOGER hydrogel enhances hMSC survival. ........................ 67 
Figure 24. hMSC and α2β1-specific GFOGER enhance bone repair. ............................. 69 
Figure 25. hMSC and α2β1-specific GFOGER result in improved tissue of repaired 
bone. .................................................................................................................................. 71 
Figure 26. Human cells detected in defect by immunostaining. ...................................... 72 
Figure 27. Discriminant analysis of gene expression. ..................................................... 91 
Figure 28. Hierarchical clustering of in vivo gene expression using Ward’s method. .... 92 
Figure 29. Defects treated with hMSC in GFOGER hydrogels exhibit differential gene 
expression profile compared to other ligands. .................................................................. 93 
Figure 30. Gene expression heat map. ............................................................................. 94 
Figure 31. Differentially expressed inflammation genes in vivo at 1 week. .................... 96 
Figure 32. Differentially expressed vascularization genes in vivo at 1 week. ................. 98 
Figure 33. Differentially expressed bone genes in vivo at 1 week. .................................. 99 
Figure 34. Discriminant analysis of cytokine secretion from encapsulated hMSC without 
IFN-γ/TNF-α stimulation. ............................................................................................... 102 
Figure 35. Hierarchical clustering of cytokine secretion from encapsulated hMSC 
without IFN-γ/TNF-α stimulation. .................................................................................. 103 
Figure 36. hMSC in GFOGER hydrogels exhibit differential secretory cytokine profile 
compared to other hydrogels without exogenous stimulation. ....................................... 104 
Figure 37. Cytokines with significant secretion levels for encapsulated hMSC without 
IFN-γ/TNF-α stimulation. ............................................................................................... 106 
Figure 38. Discriminant analysis of cytokine secretion from encapsulated hMSC with 
IFN-γ/TNF-α stimulation. ............................................................................................... 107 
Figure 39. Hierarchical clustering of cytokine secretion from encapsulated hMSC with 




Figure 40. Stimulation masks effect of ligand on cytokine secretion profile. ............... 109 
Figure 41. Cytokines with significant secretion levels for hMSC encapsulated in ligand-
functionalized hydrogels when stimulated with TNF-α and IFN-γ. ............................... 109 
Figure 42.  Roles for mesenchymal stem cells as medicinal signaling cells. ................ 115 






LIST OF ABBREVIATIONS 
 
VPM bi-cysteine peptide crosslinker containing MMP-sensitive cleavage site 
RGD GRGDSPC adhesive peptide 
GFOGER synthetic triple helical ligand containing ‘GFOGER’ hexapeptide sequence 
RDG GRDGSPC nonadhesive scrambled peptide 
GAOGER mutated synthetic triple helical nonadhesive ligand 
PEG polyethylene glycol 
PEG-mal 4-arm polyethylene glycol maleimide 
DA diacrylate 
IVIS in vivo imaging system 
BMP bone morphogenetic protein 
VEGF vascular endothelial growth factor 
rBMSC rat bone marrow stromal cells 
ECM extracellular matrix 




α2β1 alpha-2 beta-1 integrin 
αvβ3 alpha-v beta-3 integrin 





ALP alkaline phosphatase 
NSG NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ 
PS protamine sulfate 
PB polybrene 
NuMa nuclear mitotic apparatus 
MANOVA multivariate analysis of variance 
ANOVA analysis of variance 
qPCR quantitative polymerase chain reaction 
RNA ribonucleic acid 
hMSC human mesenchymal stem cells 
hMSCFLuc human mesenchymal stem cells expressing firefly luciferase 
RFLuc red firefly luciferase 
BLI bioluminescent imaging 
rhTNF-α recombinant human tumor necrosis factor alpha 
rhIFN-γ recombinant human interferon gamma 
BSA bovine serum albumin  






Despite the promising clinical results for the use of human mesenchymal stem cells 
(hMSC) in musculoskeletal defect treatment, inadequate control of cell survival, 
engraftment and fate limits the success of this cell-based therapy. Integrin-mediated cell 
adhesion plays a central role in tissue formation, maintenance, and repair by providing 
anchorage forces and triggering signals that regulate cell function. We hypothesize that 
biomaterials presenting integrin-specific adhesive motifs will direct hMSC engraftment 
and function to improve bone repair. The objective of this project is to engineer bioartificial 
hydrogels presenting integrin-specific ligands as biomimetic cell delivery vehicles for 
enhanced in vivo engraftment and function – an innovative strategy as it focuses on 
engineering specificity to integrin receptors to promote survival and cell-based repair 
without the use of exogenous growth factors. 
We investigated the performance of a cell-mediated degradable hydrogel 
functionalized with integrin-specific ligands in supporting the survival of transplanted 
hMSC and tissue repair in a segmental bone defect. This was accomplished by 
incorporating the adhesive 21 integrin-specific GFOGER ligand, adhesive v3 
integrin-specific RGD ligand, non-adhesive RDG peptide, or non-adhesive GAOGER 
peptide combined with human mesenchymal stem cells in a protease-degradable PEG-
maleimide hydrogel. Cell survival was tracked through transgenic luciferase expression 
and bone repair was monitored by microcomputer tomography. We hypothesized that 
hydrogel delivery vehicles that promoted cell viability in combination with the pro-




α2β1-specific GFOGER-functionalized hydrogels promoted enhanced hMSC survival and 
bone repair, with differential expression of vascularization and inflammation-related genes 
in vivo compared to RGD- or RDG-functionalized hydrogels, highlighting integrin-
specificity as an important consideration in the design of cell delivery vehicles for 
engraftment and tissue repair. We have generated new insights into transplanted hMSC 
survival, engraftment and function in a bone repair model allowing for direct correlations 
among hydrogel formulation and integrin specificity, transplanted cell survival, and bone 
repair outcomes. This work is significant and innovative because improved design of cell 




CHAPTER 1: SPECIFIC AIMS 
 
INTRODUCTION 
Cell-based strategies have emerged as promising therapies for the treatment of 
diseased or injured organs. Adult human mesenchymal stem cells (hMSC) constitute a 
critical component of the hematopoietic stem cell niche (microenvironment) in the bone 
marrow and have the potential to differentiate into multiple lineages, including bone, 
cartilage, and fat, while also providing immunomodulatory functions. Although hMSCs 
have shown promising results in clinical trials, inadequate control of cell fate and cell 
engraftment in host tissues significantly limits the success of this cell-based therapy. 
Integrin-mediated cell adhesion plays a central role in tissue formation, maintenance, and 
repair by providing anchorage forces and triggering signals that regulate cell function.  
The objective of my project is to engineer advanced materials using 
biofunctional hydrogels, integrin-specific ligands, and in vivo imaging for stem cell 
differentiation, delivery, and engraftment. I hypothesize that biomaterials presenting 
integrin-specific adhesive peptides will promote hMSC survival leading to improved 
engraftment and bone repair. The proposed research is innovative because it focuses on 
engineering specificity to integrin receptors to promote stem cell survival and tissue repair 
without the use of exogenous growth factors, integrates novel in vivo imaging, and utilizes 
novel hydrogel chemistry. This project will establish a defined system for hMSC 
differentiation, delivery and engraftment to treat injured tissues. The following specific 





SPECIFIC AIM 1 
Engineer integrin-specific hydrogels that support hMSC adhesion, survival, 
proliferation and differentiation in vitro.  
Two ligands of varying integrin-binding specificity will be used to examine the role 
of integrin specificity on hMSC function: RGD for αVβ3 integrin and collagen-mimetic 
GFOGER peptide for α2β1 integrin. To incorporate these ligands and protease-degradable 
cross-links, Michael addition chemistry will be utilized in a four-arm 20 kDa polyethylene 
glycol-maleimide (PEG-mal) system in which ligands and crosslinking peptides are 
functionalized with cysteine residues. This system holds many advantages over PEG-
diacrylate (DA) hydrogels (currently, the most widely used hydrogel chemistry) in that it 
avoids the use of cytotoxic free radicals and UV light, enables in situ crosslinking for in 
vivo delivery, has a well-defined structure and allows for stoichiometric incorporation of 
bioactive peptides, and avoids large degradation products consisting of non-degradable DA 
backbone. Degradable cross-links allow for cell migration, and varying the density of 
polymer controls hydrogel stiffness and degradation rate. Control groups include gels with 
scrambled or mutated, non-adhesive ligands. Ligand-incorporated hydrogels will be 
characterized in terms of material properties and specificity for integrins αVβ3 and α2β1. 
We will also determine the effect of ligand on cell functions such as proliferation, survival, 





SPECIFIC AIM 2 
Evaluate the ability of integrin-specific hydrogels to promote hMSC survival and 
bone repair in vivo. 
Using hydrogels presenting pro-osteogenic ligands and protease-degradable sites, 
hMSCs will be delivered to a non-healing segmental defect in the radii of immunodeficient 
mice. This rigorous bone repair model holds many advantages over other models – it allows 
me to evaluate the efficacy of my gels without spontaneous defect healing; the ulna 
provides sufficient stabilization for the defect, thus no need for additional fixation 
hardware; and the smaller animal model allows for easy use of in vivo imaging approaches. 
The survival and engraftment of transplanted hMSCs in integrin-specific hydrogels will be 
monitored using a luciferase reporter system. hMSCs will be transduced with a 
constitutively active red firefly luciferase (RFluc) gene to track transplanted cell numbers. 
This system reduces the number of animals, animal-to-animal variability, and permits 
direct correlations between hydrogel formulations, transplanted cell numbers, and bone 
repair. Following luciferin injections, bioluminescence will be quantified in the whole 
mouse with an In Vivo Imaging System (IVIS). At the end point of the study, hydrogels 
will be explanted and analyzed for cell numbers, differentiation and functional markers 
(bone, cartilage) using immunohistochemical techniques. Mineral quality and amount will 
be assessed using live micro-computer tomography and immunohistochemistry. I 
hypothesize that hydrogel delivery vehicles that promote cell viability in combination with 





SPECIFIC AIM 3 
Investigate the effect of integrin-specific hydrogels and hMSC on the repair 
environment in vivo. 
The ability of integrin-specific ligand-functionalized hydrogels and hMSC to 
modulate the in vivo repair environment will be characterized by vascularization and 
inflammation analyses. The effect of integrin-specific ligands on the inflammatory 
environment will first be characterized in vitro. hMSC will be encapsulated in ligand-
functionalized hydrogels and stimulated with pro-inflammatory cytokines. Secreted factors 
in the conditioned medium will be analyzed for multiple cytokines using magnetic bead-
linked immunoassays (Luminex xMAP). Hydrogel formulations identified in aims 1 and 2 
will be used to deliver hMSC in ligand-functionalized hydrogels to the murine radial 
segmental defect. Gene expression will be performed 1 week after cell transplantation. 
Genes related to vascularization, wound healing, inflammation, bone, survival, and matrix 
interactions will be analyzed on explanted tissue using high-throughput quantitative 
polymerase chain reaction (qPCR) micro array technology (Fluidigm). Lastly, the ability 
of integrin-specific ligands and hMSC to enhance vascularization in the defect will be 
assessed. Vessels will be perfused with a radio-opaque contrast agent and visualized using 
micro-computer tomography. I hypothesize that hydrogel delivery vehicles that promote 







Although hMSC have shown promising results in clinical trials, inadequate control 
of cell fate and cell engraftment in host tissues significantly limits the success of this cell-
based therapy. This work is significant and innovative because improved design of cell 
delivery vehicles may improve efficacy of current hMSC therapies in the clinic. This work 
is innovative because it focuses on engineering integrin-specificity to promote transplanted 
cell survival and modulate the repair environment for better tissue repair without the use 
of exogenous growth factors. Integration of innovative in vivo imaging approaches with 
my engineered hydrogels will generate new insights into transplanted hMSC survival, 
engraftment and function in a relevant non-healing bone repair model and allow for direct 
correlations among hydrogel formulation, transplanted cell numbers and differentiation, 





CHAPTER 2: LITERATURE REVIEW 
 
ENGINEERING THE MATRIX MICROENVIRONMENT FOR CELL 
DELIVERY AND ENGRAFTMENT FOR BONE REPAIR 1 
Clinical significance 
Cell-based therapies represent promising strategies for tissue repair, particularly in 
cases in which host cells, due to disease, age, or excessive trauma, are unable to repair the 
defect or deficiency alone, even with additional delivered therapeutics. Current cell 
therapies fail to address long term engraftment or delivery timing and location.  For 
instance, cell therapies for myocardial infarction typically consist of a cell suspension 
delivered by injection or infusion and, although proved to have an excellent safety profile, 
efficacy has been inconsistent with modest improvements at best with long term 
engraftment rates of less than 1% as the majority of delivered cells die or are washed away 
as quick as 1 hour post transplantation [1,2]. These methods not only fail to retain cells at 
the delivery site [3], but they also fail to address the effects of specific delivery location 
and timing on efficacy, factors shown to influence stem cell survival and functional 
outcome in injuries such as traumatic brain injury [4]. Long term cell engraftment has been 
shown to correlate with enhanced therapeutic outcomes [5-7], and has also been shown to 
be greater in cases in which cells are delivered in an appropriate biomaterial carrier versus 
in media alone [8]. For example, when alginate-encapsulated human mesenchymal stem 
cells (hMSC) were delivered in a hydrogel patch to injured myocardium, not only were 
                                                          
1 Adapted from:  Cheng AY, García AJ. Engineering the matrix microenvironment for cell 





improved cardiac function and reduced scarring observed compared to non-encapsulated 
hMSC in a hydrogel patch, but significantly improved retention of hMSC at the injury site 
was also observed compared to non-encapsulated hMSC in a hydrogel patch and direct 
injection of hMSC [2]. The combination of encapsulation and hydrogel patch may have 
shielded the cells from the host immune system and prevented clearance of the cells 
resulting in prolonged cell retention and a prolonged paracrine effect. Thus, in many cell 
therapy applications, an appropriate carrier must be used to deliver transplanted cells and 
promote cell engraftment and function for a successful outcome.  
The ideal carrier would provide the appropriate microenvironment for the 
interactions between transplanted and host cells. For tissue repair, as shown in Figure 1, the 
ideal carrier would result in 1. Transplanted cells integrated with host tissue and 
vascularization; 2. Replacement by healthy, normal tissue over the course of healing; and 
3. Complete function restored. 
Nonunion bone defects and bone graft substitutes 
Although bone has the innate ability to remodel and regenerate, large, non-healing 
bone defects and non-union fractures remain a significant clinical problem. Current clinical 
treatments for large bone defects   (defect length > 3 cm in forearm, > 6 cm in femur) due 
to disease, injury or tumor resection include bone grafting techniques using materials such 
as autografts or allografts, but these techniques exhibit high failure rates [9]. Autografts are 
harvested from a different site in the same patient and contain the appropriate cues, cells, 
and matrix for osteogenesis, but donor site morbidity and pain and limited tissue 
availability limit this treatment. Autografts also rely on the regenerative capacity of a 




from a different individual and may address some of the sourcing limitations of autografts, 
but carry a risk of disease transmission and immune rejection and are often processed, 
thereby reducing the biologic activity or mechanical properties of the graft [9]. Protein 
therapeutics have emerged as a promising alternative to auto- and allografts, particularly 
bone morphogenetic protein- (BMP) 2 and 7. Since the FDA’s approval in 2002, BMPs 
have mainly been used for vertebral fusions with success rates similar to autografts minus 
the need for donor tissue. However, the supraphysological dose required for the stimulation 
of bone formation leads to complications such as neuropathology, ectopic bone formation, 
and severe inflammation [10].  
Mesenchymal stem cells 
Mesenchymal stem cells (MSC) have emerged as a promising cell source for 
regenerative medicine applications for musculoskeletal deficiencies [11,12]. They are 
usually harvested from bone marrow, but have also been isolated from adipose tissue, fetal 
tissue, and skeletal muscle [13] and are multipotent, hypoimmunogenic, and can home to 
injured tissues [14]. MSC transplantation has been shown to enhance bone, cartilage, and 
intervertebral disc repair in clinical and preclinical models [15,16], but engraftment rates 
of delivered hMSCs are extremely low (<3%) [12]. The lack of information regarding cell 
fate after transplantation, cell dose, cell source, and appropriate scaffold properties limits 





Figure 1. Schematic of cell delivery vehicle performance in vivo over time.  A) Overview 
of integration of vehicle and transplanted cells into host tissue. B) Transplanted cells 
interact with host cells in many ways. Transplanted cells may release trophic or 
chemotactic factors that activate host cells and host cells in the injury site may release 
factors that drive differentiation or behavior of the transplanted cells as well as remodel the 
delivery vehicle and implant site. As cells degrade the matrix by releasing proteases, 
growth factors and other therapeutic molecules are released on demand. C) In response to 
specific adhesive ligands, growth factors, and/or soluble cues from the tissue environment, 
transplanted cells in the matrix undergo proliferation, cell-cell communication, migration 
and differentiation as the cells degrade the matrix. D) In response to pro-angiogenic growth 
factors (delivered or cell-secreted) and facilitated by adhesive ligands and matrix 
degradability, host vasculature infiltrates the matrix delivering nutrients to the transplanted 




In addition to their differentiation potential, hMSC have been reported to also 
provide anti-apoptosis, angiogenesis [17], growth factor production [18], neuroprotection 
[19], anti-fibrosis [2,20], and chemo-attraction functions [21]. They also exhibit 
immunosuppressive properties in response to allogeneic immune responses [22,23] and 
anti-inflammatory effects after activation with pro-inflammatory cytokines [24,25] 




One strategy to enhance MSC function has been forced aggregation of cells into 
aggregates or spheroids. Aggregation and culture of 3D hMSC spheroids has been shown 
to enhance anti-inflammatory and paracrine functions. hMSC spheroid or aggregates 
exhibited increased PGE2, TGF-β1 and IL-6 secretion and high suppression of 
macrophage-secreted TNFα compared to monolayer controls [26], increased TSG6 
expression [27] , and rescued expression of CXCR4, a lymphocyte and hematopoietic stem 
cell homing receptor which is lost during monolayer culture [28]. Spheroid culture of 
hMSC also significantly enhances differentiation potential resulting in increased 
osteogenic and adipogenic differentiation. These enhanced properties may be due to 
increased cell-cell contacts in the microtissue environment that more closely mimic the 
natural environment in the body compared to monolayer culture. 
 
Cell-delivery vehicle materials 
Materials used as delivery vehicles include natural materials, synthetic polymers, 
and ceramics. Natural materials such as purified collagen, hyaluronic acid, alginate, and 
chitosan have been extensively used in regenerative medicine and tissue engineering. 
Materials derived from natural sources can be biologically active, promote cell adhesion 
and growth, and enzymatically or hydrolytically degradable. However, natural materials 
display lot-to-lot variability, risk of immunogenicity and pathogen transmission, and 
structural complexity that renders modifications difficult. Calcium phosphate ceramics, 
namely tricalcium phosphate, hydroxyapatite, and bioactive glasses, are of clinical interest 
in bone tissue engineering due to their similarities to the inorganic phase of bone. Although 
these ceramics have been shown to enhance osteoblast adhesion and differentiation, their 




cell-delivery strategies that incorporate ceramics do so in combination with either natural 
or synthetic polymers as a composite material [29-31]. Synthetic polymers provide an 
alternative to natural materials as cell-delivery vehicles. Because of their defined chemical 
composition, synthetic materials are often reproducible and can be modified to control 
material properties such as degradation rate, mechanical properties, and shape. As most 
synthetic polymers lack cell adhesion sites, polymers usually need to be chemically 
modified to support cell adhesion and other bio-functionalities, and this yields the 
opportunity of engineering specificity into the material [8,32]. Tuning of the degradation 
rate is a strong advantage over ceramics and natural polymers, as synthetic polymers can 
be used to deliver therapeutic molecules at controlled and defined rates.  
A particularly attractive class of materials for cell delivery is hydrogels. Hydrogels 
are water-swollen physically or chemically cross-linked polymer networks that can be 
engineered from natural materials such as alginate or synthetic polymers such as 
polyethylene glycol (PEG). Specific advantages of hydrogels are minimal adverse host 
reactions (e.g., biocompatibility), high water content, relatively mild reaction conditions, 
and opportunity for minimally invasive delivery as injectable carriers. Hydrogels also offer 
the advantage of allowing multiple factors to be incorporated in tunable ratios creating a 
biomimetic 3D niche in which mechanical properties, presentation of bioactive molecules, 







Figure 2. Schematic of functionalized hydrogel preparation. A) Multi-arm polymer 
precursors are functionalized with adhesive ligands, growth factor tethering peptides 
(affinity-based or proteolytically labile-covalent cross-links), and growth factors. The 
addition of protease degradable cross-linkers creates a 3D hydrogel network. B) 
Alternatively, polymer chain precursors may also be functionalized with adhesive ligands 
and mixed with soluble growth factors or therapeutics to deliver untethered, but 
encapsulated molecules. Addition of cross-linkers creates a 3D hydrogel network. C) 
Cross-linking density or polymer weight percent may be tuned independently of 
functionalization. Increasing cross-link density or polymer weight percentage increases 
stiffness, but decreases diffusivity, pore size, swelling, and degradation rate. 
 
 
Matrix Stiffness/Polymer Mesh Structure  
Bulk material stiffness has been widely accepted as a driving force behind stem cell 
fate in two-dimensional cultures [33,34], but recent studies have raised the question of 
whether bulk stiffness directly determines cell fate or if bulk stiffness affects ligand 
presentation which in turn alters cell behavior [35]. Several groups have shown that stem 
cell shape in 2D can regulate cell fate [33,36,37], however, Mooney has demonstrated that 
in 3D, cell morphology is not correlated with fate and that encapsulated cells interpret 
changes in matrix stiffness as changes in adhesive ligand presentation [38]. In addition to 
matrix stiffness, Mooney has also recently shown that cells respond to matrix stress 




design parameter for biomaterials to direct encapsulated cell fate [39]. Although matrix 
stiffness and cell shape may play a role in determining cell fate in vitro, these findings are 
based on isolated, well-controlled cultures of, usually, one cell type. In vivo, the 
environment supplied by the carrier must not only provide directional cues to the 
transplanted cells, but allow for their engraftment as well as the infiltration of host cells. 
As bulk material stiffness is generally tuned by varying cross-linking density [40], polymer 
weight percent [40-42], or cross-linking chemistry [42], it is difficult to decouple the effects 
of material stiffness on encapsulated cells from the effects of cross-linking density on 
proliferation, morphological changes, migration and matrix permeability, and the effects 
that those in turn have on cell fate. For example, increasing polymer weight percentage, 
which often increases cross-linking density, or holding polymer weight percent constant 
while increasing cross-linking density decreases diffusivity which limits nutrient transport 
and increases elastic modulus [40,41], which in turn decreases the proliferation rate of 
encapsulated fibroblasts [40] and the spreading of encapsulated C2C12 murine myoblasts 
[42]. For example, the inhibitory effect from increasing matrix density and stiffness on 
capillary formation in a fibrin clot results from reduced diffusivity rather than matrix 
elasticity. When pro-angiogenic factor-secreting fibroblasts were distributed throughout 
the 3D gel, inhibitory effects from increasing fibrin density were abrogated, and capillary 
formation was equivalent between different gel densities [43]. Enemchukwu et al adjusted 
polymer weight percentages and macromer molecular weights such that each hydrogel 
formulation exhibited equivalent mean cross-link densities. They showed that although 
differences in permeability were observed due to differences in macromer arm length, 




morphogenesis between the two hydrogel formulations [44]. Undoubtedly, additional 
analyses are needed to clearly establish rational design rules for the effects of carrier 
mechanical properties and structure on cell delivery. 
Matrix degradation for tissue ingrowth and therapeutic release 
Controlled degradation of the cell carrier is critical for tissue ingrowth and cell 
migration/outgrowth as well as delivery of biotherapeutics incorporated within the carrier. 
Engineering degradability into a cell carrier can be accomplished by incorporating cross-
links that are enzymatically or hydrolytically degradable. Enzymes responsible for matrix 
degradation include matrix metalloproteinases (MMPs), which are the main class of 
enzymes used in remodeling the extracellular matrix (ECM), and hyaluronidase, the 
protease for hyaluronic acid which is found in the ECM of many connective tissues. 
Enzymatic degradation by cell-secreted hyaluronidase or MMPs can be achieved by 
incorporating cross-linking peptides that contain an MMP degradable site [32,45] or 
incorporating hyaluronic acid, mimicking the natural cell-controlled degradation of ECM. 
Degradable matrices can also be used for cell-mediated growth factor delivery with tunable 
degradation and release rates by capturing growth factors in a degradable cross-linked 
matrix [32,46,47] or by covalently or non-covalently tethering growth factors to the matrix 
using affinity-based and other motifs [48-50].  
Vascularization and co-delivery of cells and growth factors 
Many groups have reported a significant loss in transplanted cells within the first 
week after implantation [51,52]. By monitoring the kinetics of expression of three ischemic 
markers of transplanted hMSCs 30 days post-implantation, Becquart demonstrated that 




for vascularization to promote transplanted cell survival and engraftment. A material must 
be degradable to allow for the infiltration of macrophages, fibroblasts and endothelial cells 
while promoting vascularization through either the release of growth factors or other 
soluble mediators. Many groups have demonstrated that both material degradability and 
angiogenic agents can work in concert to prolong the beneficial effects of angiogenic 
therapies. Cell-demanded release of encapsulated vascular endothelial growth factor 
(VEGF) by means of matrix-metalloproteinase mediated degradation of a synthetic matrix 
significantly increased the rate of reperfusion in hind-limb ischemia [50] and produced 
extensive vascularization with functional blood vessels in hydrogels implanted 
subcutaneously [50,53] and in the mouse cornea [54]. Additionally, the delivery of VEGF 
alone to promote vascularization and bone formation has resulted in mixed reports in the 
literature with some groups reporting enhanced vascularization  and bone formation when 
delivered with a biomaterial [55,56], while other groups have shown no difference in bone 
formation even with enhanced vascularization [57-59]. An alternative strategy to increase 
angiogenesis and associated bone regeneration is the activation of the hypoxia-inducible 
factor-1α, which is the main regulator of adaptive responses to low levels of oxygen and is 
required during skeletal development [60]. The genetic or pharmacologic manipulation of 
the HIF-1α pathway has been shown to increase angiogenesis and improve bone formation 
[61-63]. Rat bone marrow stromal cells (rBMSC) genetically modified to overexpress HIF-
1α enhanced bone healing and vascularization in a rat calvarial defect model, although did 
not completely heal the defect, while control rBMSC resulted in little to no bone healing 
[64]. Another strategy for the activation of the HIF-1α pathway is the inhibition of prolyl 




Delivery of siRNA against PHD or delivery of small molecule inhibitors of PHD such as 
deferoxamine (DFO) or dimethyloxalylglycine (DMOG) increased vascularization and 
callus size formation [65,66]. The effect of co-delivery of angiogenic factors and cells on 
the engraftment and survival of the transplanted cells is rarely addressed. Delivery of 
human bone marrow stromal cells (BMSC) on a VEGF-releasing biodegradable polymer 
scaffold into a femoral defect showed increased bone formation compared to the scaffold 
alone and human BMSC-seeded scaffolds, but no comparison was provided on extent of 
engraftment or cell retention between VEGF and no VEGF groups [67].  
Many cell and growth factor co-delivery systems rely on genetically modified cells 
that produce a sustained supply of growth factors. There have been many successful in vivo 
studies in small animal models in which cells provide a constant supply of growth factors 
rather than being the therapeutic agent themselves. For example, adipose-derived stem cells 
modified to express VEGF or bone morphogenetic proteins (BMPs) significantly enhance 
bone healing [68,69], but this approach risks deleterious effects from overexpression of 
target therapeutics [46,70] and still requires a proper carrier to retain cells at the defect site 
and promote cell survival. When BMP-2 overexpressing mouse MSC were delivered to the 
mouse radial segmental defect on a collagen sponge, a significant increase in bone 
formation was observed compared to control MSC [71]. Because cell survival and released 
BMP-2 amounts were not studied, it is unknown if the increase in bone formation 
(including large amounts of ectopic bone) was due to sustained release of BMP-2 over the 
course of healing or an initial, burst release of BMP-2 followed by significant cell death. 





The host environment in a tissue injury is difficult to recapitulate in vitro due to 
multiple cell types, densely arranged cells, an inflammatory response, and vascular 
ingrowth needed to sustain transplanted cells. In order to recapitulate the cell density of 
tissues in vitro, cell density would need to be as high as 109 cells/cm3, and without a 
vascular system, this construct would fail due to inadequate nutrient supply. Multicellular 
3D tissue constructs with perfused vascular networks will enable more accurate in vitro 
study of the interactions between tissues and cell delivery systems [72]. It is noteworthy to 
mention that although it has been shown that co-delivery of VEGF and cells can improve 
bone formation, few groups have directly addressed the effect of exogenous VEGF on cell 
engraftment and survival in bone regeneration, most likely due to focus being placed on 
the bone healing properties of VEGF rather than its pro-angiogenic effects on cell survival. 
Most in vivo cell-delivery studies in bone repair use new bone formation and/or mechanical 
testing as indicators of therapy efficacy and do not address cell engraftment or, at the bare 
minimum, provide evidence that some transplanted cells are present at the end of the study. 
Cell engraftment is rarely studied as a means to improve functional outcome which raises 
the question of whether cell engraftment is important if the overall outcome, i.e. functional 
restoration of the injured tissue, is improved. 
Cell adhesive interactions 
An appropriate carrier must support the adhesion, migration, organization, and 
differentiation of the transplanted cells and host cells. These behaviors rely on an intricate 
interaction between various cues supplied by the extracellular environment which include 
insoluble molecules within the ECM such as proteins, soluble molecules such as growth 




surface receptors that primarily mediate adhesion of cells to ECM proteins and also 
transduce signals across the cell membrane. Each αβ heterodimeric combination exhibits 
unique binding characteristics and mediates cellular activities such as migration, 
proliferation, survival and differentiation [73]. Therefore, as a major mediator of important 
cellular responses, engineering integrin binding activity within a 3D environment may 
improve transplanted cell survival and function. As synthetic polymers such as 
polyethylene glycol have become a popular choice for biomaterials for their non-fouling 
properties, additional steps must be taken to functionalize these synthetic materials to 
promote cell adhesion. Encapsulating fibroblasts in a polyethylene glycol hydrogel with 
protease-degradable sites, RGD, neither or both demonstrated that both adhesive sites and 
degradability were required for cell spreading and migration within a 3D synthetic 
hydrogel carrier [45,50].  
Materials may be functionalized to promote adhesion by 1. Incorporating small 
adhesive ligands, such as RGD oligopeptides [32,42,50,74]; 2. Components found in ECM 
such as collagen [75] or hyaluronic acid [76]; or 3. Functionalizing with small chemical 
groups, such as phosphates, to promote specific protein interactions [77]. There has been 
some degree of success using full length ECM proteins to functionalize biomaterials by 
tethering or passive adsorption, but these proteins come with batch to batch variability, 
limited control over presentation, and difficulty in making modifications. For example, 
α2β1 binds the sequence GFOGER, one of the major recognition sites on type I collagen 
[78], which makes up more than 90% of the organic phase of bone. When compared to full 
length type I collagen, the GFOGER collagen-mimetic peptide significantly improved in 




contact area and mechanical fixation [79]. Use of a non-fouling material, such as PEG, 
allows for engineering integrin specificity in the cell carrier by incorporation of specific 
adhesive ligands. GFOGER-functionalized PEG hydrogels resulted in healing of 30% of 
murine radial segmental defects, and when combined with low doses of BMP-2, full 
bridging of 100% of segmental defects was achieved [80]. RGD, the shortest known 
adhesive sequence, is found in many proteins such as fibronectin, vitronectin, bone 
sialoprotein, and osteopontin [81], and promiscuously binds to a number of integrin 
receptors. Although RGD helps to mediate functional vascularization, the integrins specific 
for RGD may not be appropriate for every tissue engineering application. Emerging 
evidence supports a role for integrin binding specificity in directing cellular responses to 
biomaterials [82]. RGD-functionalized biomaterials generally failed to promote bone 
healing, with [51,83] or without encapsulated cells [80].  When RGD is combined with 
synergy site PHSRN from fibronectin in the correct structural presentation, affinity for 
integrin α5β1 increases 40-fold compared to RGD alone [84,85]. β1 integrins have been 
shown to contribute to bone marrow cell adhesion, mineralization, and bone healing and 
α5β1 is present on osteoblasts and osteoclasts during all stages of osteogenesis. Titanium 
implants functionalized with a fibronectin fragment specific for α5β1 performed 
significantly better in an osseointegration study compared to RGD functionalization in 
terms of pull-out force and bone-implant contact area [85], consistent with other reports in 
the failure of RGD to promote functional osseointegration [86].  
Engineering specificity of short peptide ligands to integrins is dependent on affinity 
of the receptor for the ligand as well as the expression levels of the receptor subunits on 




α2β1, α10β1, and α11β1, which have all been previously reported to be expressed by 
hMSC at differential levels [87]. α1β1, expressed at low basal levels on hMSC, was not 
required for hMSC survival on collagen I and did not exhibit an increase in expression 
upon osteogenic differentiation, whereas α2β1 and α11β1 were required for survival of 
hMSC on Collagen I and exhibited increased expression upon osteogenic stimulation [88]. 
α10β1 is also expressed at low basal levels on hMSC and is mainly restricted to cartilage 
[89,90].  The hexapeptide GFOGER was originally identified as the major binding 
sequence of integrin α2β1 [91,92], but since then, has been reported to also bind integrins 
α1β1, α10β1, and α11β1 [92,93]. Although the newly discovered α11β1 also recognizes 
GFOGER, Zhang et al report a significantly lower affinity of α11β1 to collagen I compared 
to α2β1 [94]. Due to the low expression of α1β1 and α10β1 on hMSC, and the low affinity 
of α11β, within the scope of this project, GFOGER will be referred to as integrin α2β1-
specific. RGD promiscuously binds to a number of receptors and can be found in many 
ECM proteins, but the linear secondary structure of RGD has been shown to preferentially 
mediate hMSC adhesion through integrin αvβ3 [85], although still binding other integrins 




Bioluminescent imaging has emerged as a powerful tool for monitoring gene 
expression or tracking cells in vivo. Bioluminescence is produced during the reaction 
between the luciferase enzyme and its substrate and has been used in various applications, 
including bone tissue engineering [95-98]. Because different luciferase variants react with 




multiple types of luciferase to track multiple gene targets in the same cell [99,100]. In vivo 
imaging provides sensitive measurements of cell numbers and longitudinal data on 
transplanted cells within the same subject population [97]. This system reduces the number 
of animals, animal-to-animal variability, and permits direct correlations between cell 
delivery vehicles design and transplanted or differentiated cell numbers. 
Bioluminescent imaging provides many advantages over other cell tracking 
modalities. Because the light-emitting reaction does not require an excitation source, unlike 
fluorescent proteins, there is very little background. The enzyme luciferase is only 
expressed by live cells, which provides an advantage over quantum dot or nanoparticle 
based tracking which may confound results if materials are phagocytosed by other cell 
types. Although bioluminescence exhibits many advantages, there are still limitations to 
this method. The stable expression of the foreign luciferase gene must be induced by means 
of viral transduction. Because most bioluminescent tracking schemes require the 
exogenous delivery of the appropriate substrate, usually through a systemic injection into 
the intraperitoneal cavity, the kinetics of the substrate movement first, to the defect site, 
and second, into the implant material to the transplanted cells, must be determined for each 
model. As with all cell tracking modalities, though, the signal must be validated as 









Hydrogels are an attractive class of materials for cell encapsulation due to 
properties that mimic the extracellular matrix such as high water content and simple 
diffusion of waste and nutrients, minimal adverse host reactions, relatively mild reaction 
conditions, and opportunity for minimally invasive delivery as injectable carriers. Due to 
their defined chemical compositions, synthetic polymers can be prepared in reproducible 
and predictable fashions and can be modified to tune material properties such as 
degradation rate, mechanical properties, and shape/configuration - large advantages over 
natural polymers that display heterogeneity and structural complexity that renders 
modifications difficult. The lack of cell adhesion sites on most synthetic polymers yields 
the opportunity for engineering specificity into the material by incorporating cell adhesive 
sites or growth factors, independently of substrate mechanical properties. In this aim, we 
have engineered an integrin-specific stem cell microenvironment using biomimetic 
adhesive ligands using a novel hydrogel chemistry without the use of cytotoxic photo-
initiators and UV light. We have shown that we can control material properties of the 
matrix independently of ligand peptide and tune material properties such as storage 
modulus by varying hydrogel parameters. Ligand-functionalized hydrogels exhibited 
binding specificity to target integrins, and we observed differences in cell morphology in 
3-D due to ligand activity while maintaining high cell viability. In addition, integrin-




differentiation as compared to hydrogels presenting non-adhesive control peptides. This 
study supports ligand-functionalized PEG-mal hydrogels as a viable carrier for hMSC 





Hydrogels have emerged as an attractive class of materials to engineer cell 
microenvironments [102,103]. Hydrogels are water-swollen, physically or chemically 
cross-linked polymer networks that can be engineered from natural materials such as 
alginate or synthetic polymers such as poly(ethylene glycol) (PEG). Specific advantages 
of hydrogels are minimal adverse host reactions, high water content, relatively mild 
reaction conditions, tissue-like elastic properties and opportunity for minimally invasive 
delivery as injectable carriers. Hydrogels also offer the advantage of allowing multiple 
factors to be incorporated in tunable ratios creating a biomimetic 3-D niche in which 
mechanical properties, presentation of bioactive molecules, and degradation of the gel can 
be tuned independently. An elegant example where the biophysical and biochemical 
properties of the hydrogel were systematically varied to regulate the complex epithelial 
morphogenesis program has been recently described [44].  
The earliest materials used for cell encapsulation, namely fibrin, collagen, and 
alginate, were naturally occurring and biodegradable, and demonstrated promise in early 
studies [104-106]. Although these naturally-derived materials may be biologically active, 
promote cell adhesion and growth, and may be enzymatically or hydrolytically degradable, 
they display lot-to-lot variability, risk of immunogenicity and pathogen transmission, and 
structural complexity that renders control over degradation or gelation rates difficult. 
Synthetic polymers provide an alternative to natural materials as cell microenvironments. 
Because of their defined chemical composition, synthetic materials can be reproducibly 
prepared and can be modified to control material properties such as degradation rate, 




synthetic polymers used for hydrogels lack cell adhesion sites and are relatively resistant 
to protein adsorption, they usually need to be chemically modified to support cell adhesion 
and other bio-functionalities, and this yields the opportunity of engineering specificity into 
the material [8,32]. Poly(ethylene glycol) (PEG) holds many advantages as a synthetic 
polymer hydrogel building block. It exhibits low protein adsorption, providing a non-
fouling background, a minimal inflammatory profile, well-established chemistry, and a 
long history of safety in vivo. Maleimide-thiol hydrogel chemistry with maleimide end-
functionalized PEG macromers and cysteine-terminated peptides allows for mild reaction 
conditions at high reaction efficiencies, small degradation products, and “plug-and-play” 
functionality [42]. This system holds many advantages over PEG-diacrylate (DA) 
hydrogels (currently, the most widely used hydrogel chemistry) in that it avoids the use of 
cytotoxic free radicals and UV light, enables in situ crosslinking for in vivo delivery, has a 
well-defined structure and allows for stoichiometric incorporation of bioactive peptides, 
and avoids large degradation products consisting of non-degradable DA backbone. 
Additionally, the base macromer has no local or systemic toxicity and is rapidly cleared 
via the urine. Exemplary applications of this system include islet transplantation, growth 
factor delivery for cardiac therapy, and low dose BMP-2 delivery for bone healing 
[2,107,108]. 
The hydrogel scheme and molecules used in this project are outlined in Figure 3. 
Four-arm, maleimide-end functionalized 20 kDa PEG macromer was reacted with one of 
four cysteine-terminated peptide ligands: 1. αvβ3-specific linear RGD, 2. α2β1-specific 




GAOGER; and cross-linked with the cysteine-flanked VPM peptide containing a protease-
degradable site.  
 
 
Figure 3. Protease-degradable PEG hydrogel reaction scheme.  A) Cell-laden 4 arm-PEG-
maleimide hydrogel reaction scheme (cells not shown to scale relative to hydrogel). B) 
Hydrogel components consist of 4-arm PEG-mal, peptide ligands RGD, GFOGER, RDG, 






Ligand tethering efficiency 
Four-arm, maleimide-end functionalized (>95%) PEG macromer (PEG-mal, 20 
kDa, Laysan Bio) was reacted with GFOGER peptide 
(GGYGGGPG(GPP)5GFOGER(GPP)5GPC, O = hydroxyproline), RGD peptide 
(GRGDSPC), or the scrambled, non-adhesive RDG peptide (CRDGSPC) in 10 mM 
HEPES in PBS, pH 7.4 for 15 min at 37 ºC. The reaction diluted in PBS 100-fold and 
diluted PEG-adhesive peptide (10 μL) plus thiol-quantitation reagent (100 μL, Measure-iT 
Thiol Assay Kit, Thermo Fisher) was added per well of a 96-well plate and read using a 
microplate reader. Dilutions of GFOGER, RGD, or RDG in 10 mM HEPES in PBS were 
used as standards. All samples and standards were measured in triplicate. 
Hydrogel Synthesis 
20 kDa PEG-mal, adhesive and control peptides (GFOGER, RGD, RDG, 
GAOGER), GCRDVPMSMRGGDRCG (VPM) cross-linker peptide, and dithiothreitol 
(DTT, Sigma Aldrich) in 100 mM HEPES in PBS, pH 6-6.5 were used. The peptide 
sequences and hydrogel components are listed in Table 1. PEG-mal hydrogels were 
synthesized by reacting PEG-mal with adhesive peptides, a 75:25 cross-linker mixture of 
VPM:DTT, and 10 mM HEPES  at a volume ratio of 2:1:1:1 at the required concentrations 
to obtain the desired final concentration of PEG-mal and adhesive peptide. The 
concentration of cross-linker used for the synthesis of each hydrogel was calculated to 
stoichiometrically balance the number of free thiols on the cross-linker with the number of 
free (unreacted) maleimide groups remaining in the adhesive peptide-functionalized PEG-




by mixing PEG-mal, adhesive peptide, 75:25 VPM:DTT, and cell suspension at a volume 
ratio of 2:1:1:1 and allowed to cross-link at 37 ºC before swelling with media.  
 
Table 1. Peptide hydrogel components. 
Abbreviated 
name 
Peptide sequence Source 
VPM GCRDVPMSMRGGDRCG AAPPTEC, Genscript 
RGD GRGDSPC AAPPTEC 
RDG GRDGSPC AAPPTEC 









12.5 μL hydrogels were cast as discs in 4.5 mm diameter silicone isolators (Grace 
Bio-Labs, Sigma) on Sigmacote-treated slides (Sigma). The gels were allowed to cross-
link at 37 ºC, removed from the isolators, and swollen in PBS overnight. Rheological 
measurements were made using a cone and plate rheometer (MCR302, Anton Paar). The 
sample was loaded onto the plate, the cone was lowered, and excess sample was removed. 
Storage and loss moduli were measured over a range of angular frequencies with a strain 
that corresponded to the linear viscoelastic region.   
Swelling Studies 
50 μL hydrogels were allowed to cross-link at 37 ºC and swollen in PBS overnight. 
Swollen hydrogels were weighed and snap frozen in liquid nitrogen. Following 










Mesh Size Calculations 
 Mesh size was calculated using several methods: 1. rheological 
measurements and rubber elasticity theory [109], and swelling measurements and the Flory 
and Rehner equation modified by Merrill and Peppas [110,111] based on 2. experimental 
data or 3. theoretical values. Rubber elasticity theory relates mesh size, ξ, to storage 










where R is the molar gas constant and T the temperature. Swelling measurements 

















































where 𝑣2,s and 𝑣2,r are the polymer volume fraction of the gel in the swollen and 
relaxed states, respectively, (?̅?0
2)
1
2 is the unperturbed mean-square end-to-end distance of 
the PEG, 𝑙 is the average value of the bond length = 1.46 Å, ?̅?𝑐is the average molecular 
mass between the cross-links in the network (experimental value calculated from equation 




molecular mass of PEG repeating unit (44 g/mol), 𝐶𝑛is the characteristic ratio of PEG = 4, 










, 𝑉1is the molar volume of the solvent 
(18 cm3/mol for water), and χ is the polymer-solvent interaction parameter (0.4 for PEG-
water). 
hMSC Culture 
Bone marrow-derived hMSC (Texas A&M) were maintained in growth media: 
αMEM (Thermo Fisher) with 16.5% fetal bovine serum screened for hMSC growth (Stem 
Cell Tech), 2-4 mM L-glutamine (Thermo Fisher), 100 units/mL penicillin , and 100 μg/mL 
streptomycin at 37 ºC, 5% CO2. hMSC were sub-cultured at 70-80% confluency, and for 
all experiments early passage (<6) cells were used. 
Adhesion Studies 
20 µL of 6% (wt/v) hydrogels with 1.0 mM ligand were cast on the bottom of a 
well on a 48 well plate covering the entire surface. hMSC were incubated with anti-α2 
integrin (Millipore), anti-αvβ3 integrin (Millipore), mouse IgG1 isotype control (R&D 
Systems) at 10 µg/mL, or without antibody, and then seeded on top of hydrogel discs at 
7000 hMSC/cm2. After 15 min, hMSC were rinsed with PBS and fixed in 4% 
paraformaldehyde. Nuclei were then stained with 4′,6-diamidino-2-phenylindole (DAPI, 
Life Technologies) and visualized with a Nikon C2+ laser scanning confocal head on a 
Nikon Eclipse-Ti microscope and Elements software (Nikon).  Images were analyzed for 






hMSC-laden hydrogels were cultured free-floating in media and at specified time 
points, stained with Calcein AM (Thermo Fisher) for live hMSC and ethidium homodimer 
(Life Technologies) for dead hMSC. Gel-encapsulated hMSC were visualized with a Nikon 
C2+ laser scanning confocal head on a Nikon Eclipse-Ti microscope and Elements 
software (Nikon). Maximum projections on z-stacks were analyzed using ImageJ (NIH). 
Cell number 
At specified time points, hydrogels were incubated in 1 mg/mL collagenase, type I 
(Thermo Fisher) at 37 ºC until fully degraded. Cells were lysed by sonication and freeze-
thaw cycles. Whole cell lysate was assayed for DNA content and cell number using a 
CyQuant kit according to manufacturer’s instructions (Thermo Fisher) and a cell standard 
curve.  
EdU Staining for Cell Proliferation 
hMSC-laden hydrogels were cultured free-floating in media. At day 7, cells were 
incubated with 10 μM EdU for 48 hr. EdU detection was visualized using a Click-iT EdU 
kit according to manufacturer’s instructions (Thermo Fisher). Nuclei were stained with 
DAPI and visualized with a Nikon C2+ laser scanning confocal head on a Nikon Eclipse-
Ti microscope and Elements software (Nikon) and images were analyzed using ImageJ 
(NIH). 
Osteogenic differentiation – 3-D 
hMSC were seeded at 5e6 cells/mL within 4.5% or 10% (wt/v) hydrogels with 1.0 
mM ligand and cultured in osteogenic medium (Lonza). After 9 days of culture in induction 




incubating with 4-methylumbelliferyl phosphate disodium salt (MUP) substrate as 
previously described [112]. Hydrogels were incubated in 1 mg/mL collagenase type I 
(Thermo Fisher) at 37 ºC until fully degraded. Cells were resuspended in 50 mM Tris HCl 
(pH 7.4) and lysed by sonication and freeze-thaw cycles. Samples and ALP standards were 
loaded into a 96-well plate, then incubated with 60 μg/mL MUP substrate at 37 ºC for 1 hr 
and read at 360 nm excitation/465 nm emission. The enzymatic activity was standardized 
using purified calf intestinal ALP at known dilutions and normalized to the amount of DNA 
content using a CyQuant kit according to manufacturer’s instructions (Thermo Fisher). 
FAK Phosphorylation 
hMSC were encapsulated and cultured in ligand-functionalized hydrogels 
overnight. Cells were washed twice with PBS and lysed by sonication on ice in cell 
extraction buffer containing protease and phosphatase inhibitors (Thermo Fisher). The 
lysates were cleared by centrifugation at 10,000 rpm for 15 min at 4 °C and extract was 
stored at -80 until analysis. Protein concentration was determined using a micro BCA kit 
(Pierce). Equivalent amounts of reduced, boiled (10 min at 70 ºC) lysate were loaded on 
Bolt 10% Bis-Tris Plus gels (Thermo Fisher) and subsequently transferred onto PVDF 
membranes. Membranes were probed with mouse monoclonal antibody against GAPDH 
(Abcam), mouse monoclonal antibody against FAK and rabbit polyclonal antibody against 
FAK [pY397] (Thermo Fisher) at a 1:1000 dilution in 5% BSA TBST solution followed 
by fluorescent secondary antibodies (Li-Cor). Immunoblots were visualized on a Li-Cor 






Characterizing hydrogel material properties 
We first examined the effects of ligand functionalization on bulk material 
properties. Tethering efficiency of peptide ligands GFOGER, RGD, and RDG to PEG-mal 
macromer was evaluated. PEG-mal was reacted with ligand at concentrations for a 1.0 mM 
ligand or 0.3 mM ligand hydrogel. Unreacted thiols were quantified using a thiol-reactive 
fluorescent dye. Figure 4A shows that GFOGER, RGD, and RDG all react with PEG-mal 
at high efficiency (>95%) and tethering efficiency is not affected by ligand concentration. 
Rheological properties were then quantified for ligand-functionalized hydrogels on a cone 
and plate rheometer. 4.5% (w/v) PEG-mal, 1.0 mM ligand hydrogels were cast in silicone 
isolators (to maintain uniform shape) and swollen overnight. The storage modulus (G’) was 
determined over a range of angular frequencies at a constant strain. GFOGER, RGD, and 
RDG-functionalized hydrogels exhibited storage moduli of 64.7, 61.8, and 61.1 Pa, 
respectively, but were not significantly different, (Figure 4B) and loss moduli of 2-5 Pa 
(data not shown). The mass swelling ratio was determined for 4.5% (w/v) PEG gels 
presenting 1.0 mM GFOGER and RGD as the ratio of the wet, swollen weight to the dry 
weight. Figure 4C shows mass swelling ratios of 38.7 and 36.4 for GFOGER and RGD, 
respectively; these ratios are not statistically different. Mesh size is a measure of the 
distance between cross-links and controls the diffusion of nutrients, signaling molecules, 
and waste. Mesh size was estimated by three methods: rubber elasticity theory, Flory and 
Rehner equations with experimentally determined molecular mass between cross-links, 
and Flory and Rehner equations with theoretical molecular mass between cross-links. All 




Table 2 shows estimated mesh sizes in the range of 15-40 nm for the three calculation 
methods, with no statistical difference among ligands. In addition, hydrogels containing 
1.0 mM GFOGER were made at different PEG weight percentages ranging from 4.5% to 
3%. Figure 5 shows the decreasing storage moduli as PEG weight percent decreases, as 
expected due to increasing cross-linking density in higher weight percent gels. Estimates 
of mesh size for each weight percent were calculated using rubber elastic theory as 39 nm, 




Figure 4. Ligand tethering efficiency and material properties.  A) Quantification of free 
thiols in solution following reaction of PEG-mal and ligand at two different ligand 
concentrations indicates virtually all ligand reacted with PEG-mal is functionalized to the 
end maleimide groups. (Bar represents mean, error bars represent SD). B) Storage moduli 
of bulk hydrogels determined by cone and plate rheological measurements. C) Mass 
swelling ratios of bulk hydrogels. (Whiskers represent min and max, box extends from 25th 





Table 2. Mesh size calculations for a 4.5% (w/v) PEG hydrogel with 1 mM ligand. 
 
Ligand ξ ± S.D. (nm)a ξ ± S.D. (nm)b ξ ± S.D. (nm)c 
GFOGER 40 ± 0.7 18 ± 0.7 23 ± 0.5 
RGD 40 ± 1.4 17 ± 0.8 22 ± 0.5 
RDG 41 ± 1.0 - - 
a Calculated by rubber elasticity theory and rheological measurements 
b Calculated by Flory and Rehner equations with experimental ?̅?𝑐 





Figure 5. Rheology of varying weight percent hydrogels. Storage moduli of bulk hydrogels 
with 1 mM GFOGER determined by cone and plate rheological measurements. (Whiskers 
represent min and max, box extends from 25th to 75th percentiles, line represents median. 
N=5; ANOVA: *p<0.05, **p<0.005,***p<0.001). 
 
Integrin specificity of GFOGER and RGD hydrogels 
Integrin specificity of ligand-functionalized hydrogels was determined by studying 
short term adhesion of hMSC on top of thin hydrogels with and without incubation in 
function-blocking antibodies for integrin α2 or integrin αvβ3. When hMSC were incubated 
with anti-α2 antibody and seeded on top of GFOGER-functionalized hydrogels, there was 




antibody incubation (Figure 6A). When hMSC were incubated with anti-αvβ3, there was 
~75% reduction in adherent cells compared to hMSC on RGD hydrogels without antibody 
incubation (Figure 6B). Minimal hMSC adhesion was observed on hydrogels without 
ligand or on RDG functionalized hydrogels. For both GFOGER and RGD hydrogels, there 
was a slight decrease in the number of adherent cells when incubated with the isotype 
control suggesting that the nonspecific antibody interactions influenced the number of 
adherent cells, although not significantly different from hMSC on ligand-functionalized 
hydrogels without antibody incubation. Antibody blocking of target integrins did not 
completely block cell adhesion to the ligand-functionalized hydrogels, likely due to 
robustness of the wash assay used in this study to apply controlled detachment forces. A 
more robust adhesion assay, such as the spinning disk assay, may offer finer control over 




Figure 6. Integrin-specificity of ligand-functionalized hydrogels.  A) Antibody-mediated 
blocking of α2 integrin on hMSC reduces adhesion on thin GFOGER-functionalized 
hydrogels. B) Blocking αvβ3 integrin on hMSC reduces adhesion on thin RGD-
functionalized hydrogels. (Whiskers represent min and max, box extends from 25th to 75th 





Effect of encapsulation on hMSC viability 
We then assessed hMSC behavior in 3-D ligand-functionalized hydrogels. hMSC 
were encapsulated in 4.5% 1.0 mM GFOGER, RGD or RDG functionalized hydrogels. 
After 7 days in culture, live cells were stained with cell-permeant Calcein AM and dead 
cells were stained with cell-impermeant ethidium homodimer. Maximum projections of 
representative z-stacks taken by confocal microscopy are shown in Figure 7A with Calcein 
AM in green and ethidium homodimer in red. Insets show high magnification images of 
actin staining with phalloidin and nuclei staining with DAPI. Cell viability and spreading 
area was quantified by analyzing staining with image analysis. Calcein AM and ethidium 
homodimer stain area was quantified for individual maximum projections of multiple z-
stacks, and the live cell percentage was determined as the ratio of Calcein stain area to 
ethidium homodimer stain area. Figure 7B shows 91.6%, 93.6% and 87.5% live cells for 
GFOGER, RGD, and RDG gels respectively. The viability percentage for RDG hydrogel 
was significantly lower than RGD. Cell area was quantified as Calcein stain area as this 
label stains the entire cell body. GFOGER and RGD exhibited higher spread area (17.2% 
and 14.7%) compared to the non-adhesive RDG (7.1%). Networks consisting of multiple 
cells and elongated cells were observed in GFOGER and RGD functionalized gels whereas 
in RDG gels, cells remained single and round, or formed small multi-cell clusters or 
aggregates (Figure 7C). No significant difference was observed in results obtained from 






Figure 7. Viability and spreading of encapsulated hMSC.  A) Encapsulated hMSC were 
cultured for 7 days and stained with Calcein AM (green) and ethidium homodimer (red). 
Inset shows high magnification view of actin (red) and nuclei (cyan). B) Quantification of 
viability staining indicates high viability (>90%) in GFOGER- and RGD-functionalized 
hydrogels. C) Quantification of spread cell area indicates significantly more spreading in 
GFOGER- and RGD-functionalized hydrogels compared to non-adhesive RDG-
functionalized hydrogel. (Whiskers represent min and max, box extends from 25th to 75th 
percentiles, line represents median. N=4-5; ANOVA: *p<0.05; Kruskal-Wallis: #p<0.05). 
 
 
GAOGER control hexapeptide 
An inactive control peptide was designed to account for the size and structure of 
GFOGER. The phenylalanine in the GFOGER sequence was replaced with alanine to 
significantly reduce integrin binding and adhesion while the rest of the peptide sequence 
was conserved [114]. When hMSC were seeded on top of GFOGER, GAOGER, or no 
ligand hydrogels, minimal adhesion was observed on GAOGER hydrogels or hydrogels 




viability of encapsulated hMSC after 1 week in culture, GAOGER functionalization 




Figure 8. Mutated, non-adhesive peptide control for GFOGER does not support cell 
adhesion.  Phenylalanine in GFOGER sequence was replaced with alanine to block integrin 
binding. Minimal hMSC adhesion was observed on GAOGER-functionalized hydrogels. 
(Whiskers represent min and max, box extends from 25th to 75th percentiles, line represents 





Figure 9. GAOGER does not support spreading of encapsulated hMSC.  hMSC were 
encapsulated in GFOGER or GAOGER functionalized hydrogels. After 7 days in culture, 
hMSC were stained with Calcein AM and ethidium homodimer. A) Quantification of 
viability staining indicates high viability (>90%) in GFOGER- and GAOGER-
functionalized hydrogels. B) Quantification of spread cell area indicates significantly more 
spreading in GFOGER-hydrogels compared to non-adhesive GAOGER-functionalized 
hydrogel. (Whiskers represent min and max, box extends from 25th to 75th percentiles, line 





Integrin-mediated signaling requires the recruitment of many intracellular proteins 
to the focal adhesion, including focal adhesion kinase (FAK), a key regulator of adhesion 
and motility [115,116]. As a result of integrin binding, tyrosine and serine residues are 
phosphorylated leading to the formation of docking sites for a variety of signaling 
molecules. In particular, tyrosine 397 is the autophosphorylation site of FAK and is 
involved in its initial activation, binding Src family SH2 domains and the p85 subunit of 
PI3-kinase [117]. GFOGER and RGD hydrogel functionalization led to increased levels of 
FAK-Y397 phosphorylation of encapsulated hMSC compared to their inactive peptide 
controls (1.5-fold increase in GFOGER vs. GAOGER and 1.4-fold increase in RGD vs. 
RDG, Figure 10). The phosphorylation of FAK combined with the spread cell morphology 
in 3-D indicates that encapsulated hMSC are able to initiate integrin binding with the 
peptide ligands which activates focal adhesion signaling.  
 
 
Figure 10. Western blot for FAK phosphorylation.  hMSC exhibited 1.5- and 1.4- fold 
greater phosphorylation of FAK at Y397 when encapsulated in hydrogels functionalized 





Encapsulated hMSC growth and proliferation  
We next examined the behavior of hMSC encapsulated in ligand-functionalized 




culture. Figure 11 shows no significant differences in initial cell loading on day 1 or cell 
number on day 7 among GFOGER, RGD, or RDG hydrogels. There was also no siginficant 
difference between days 1 and 7 for any of the ligands. 
 
 
Figure 11. Encapsulated cell number in ligand-functionalized hydrogels.  Cell number over 
1 week in culture was assessed for cell-laden ligand-functionalized hydrogels. No 
significant differences were detected between time points or among groups. (Whiskers 





We then examined proliferation of hMSC inside ligand-functionalized hydrogels 
by incorporation of 5-ethynyl-2'-deoxyuridine (EdU), a nucleoside analog of thymidine 
which is incorporated into DNA during active DNA synthesis. hMSC-laden hydrogels 
were cultured for 7 days and then exposed to EdU for 48 h. EdU incorporation was detected 
by covalently binding a fluorescent azide using click chemistry. Figure 12 shows low 
proliferation rates with median values around 2%.  Proliferation rates were not significantly 







Figure 12. Proliferation of encapsulated hMSC in ligand-functionalized hydrogels.  
Proliferation was assessed by EdU incorporation (48 hr exposure) after 1 week in culture 
of encapsulated hMSC. No significant differences were detected among ligands. (Whiskers 




Osteogenic differentiation of encapsulated hMSC 
To examine osteogenic differentiation, alkaline phosphatase activity, an early 
marker of osteogenic differentiation, was assessed. hMSC were encapsulated in ligand-
functionalized hydrogels and cultured in osteogenic media or growth media. Alkaline 
phosphatase activity was measured and is shown in Figure 13. For cell laden hydrogels 
functionalized with the adhesive peptides GFOGER or RGD, ALP levels for osteogenically 
stimulated samples were 3-fold higher than growth controls, whereas ALP levels for hMSC 






Figure 13. Osteogenic differentiation of encapsulated hMSC.  Cell-laden hydrogels were 
cultured in osteogenic induction medium. Alkaline phosphatase activity, an early marker 
of differentiation, was assessed on day 9. (Whiskers represent min and max, box extends 







Hydrogels are an attractive class of materials for cell encapsulation due to 
properties that mimic the extracellular matrix such as high water content and simple 
diffusion of oxygen, nutrients, and waste. Due to their defined chemical compositions, 
synthetic polymers are often reproducible and can be modified to tune material properties 
such as degradation rate, mechanical properties, and shape - large advantages over natural 
polymers that display heterogeneity and structural complexity that renders modifications 
difficult. The lack of cell adhesion sites on most synthetic polymers yields the opportunity 
of engineering specificity into the material by incorporating cell adhesive sites or growth 
factors, independent of substrate mechanical properties.  
PEG-mal hydrogels have been successfully used in a wide array of applications: 
the  study of epithelial morphogenesis [44], a therapeutic neural electrode coating [118], 
enhancement of islet survival after transplantation [107], cell delivery and growth factor 
delivery for cardiac repair after injury [2,108], growth factor delivery for bone repair [80], 
and skeletal muscle constructs [119]. This study aimed to develop PEG-mal as a novel, 
integrin-specific microenvironment and cell-delivery vehicle for hMSC. 
We found that GFOGER, RGD and RDG all exhibited high conjugation 
efficiencies to PEG-mal, which is a significant advantage compared to other Michael 
addition chemistries with reactivity towards thiols [42]. The bulk material properties 
storage modulus and swelling ratio were not different among ligands for hydrogels of the 
same weight percent and ligand density. However, because of the large difference in the 
structure and size of the ligands – GFOGER is a 12 kDa triple helix and RGD/RDG are 




material properties, or ligand accessibility among hydrogels containing different peptides. 
Rubber elasticity theory and the Flory and Rehner equations estimated the mesh size of our 
hydrogels at 15-40 nm, within the range of other published PEG hydrogel mesh sizes 
[111,120]. Cell adhesion 2-D experiments on the surface of peptide-functionalized gels 
showed that the adhesive peptides RGD and GFOGER were active after conjugation and 
crosslinking in the hydrogel platform. Antibody blocking experiments showed that short 
term hMSC adhesion was largely mediated by integrin α2β1 on GFOGER hydrogels and 
by integrin αvβ3 on RGD hydrogels, consistent with previous reports [78,85]. As expected, 
RDG and GAOGER peptide control hydrogels supported little hMSC adhesion, similar to 
blank hydrogels. It is noteworthy to discuss the stiffness of our hydrogel formulation 
compared to many other hydrogel compositions in the field used for osteogenic 
differentiation. Although matrix stiffness and cell shape may play a role in determining 
cell fate in vitro [33,36,37], in vivo, the transplanted microenvironment must not only 
provide directional cues to the transplanted cells, but allow for their engraftment as well as 
the infiltration of host cells. Because the ultimate aim of this project was to engineer a 
microenvironment for cell delivery and tissue repair, the hydrogels used in this study were 
relatively soft (G’=60 Pa) compared to other published studies (G’ = 100-1000 Pa [121], 
G’ = 4-7 kPa [39], σ = 1-50 kPa [122,123] ). Previous work in our lab and others have 
shown that less cross-linked and more degradable hydrogels, result in better healing in vivo 
[32,50,80], thus we decided to move forward with in vitro characterization of hydrogels 
that would closely mimic what we used for cell delivery in vivo.  
Encapsulation in adhesive RGD and GFOGER hydrogels resulted in high viability 




fibers. Significantly less spreading and diffuse actin staining was observed in RDG and 
GAOGER hydrogels, consistent with the 2-D cell adhesion results in that RDG and 
GAOGER do not support cell adhesion. The levels of FAK phosphorylation were higher 
in GFOGER and RGD hydrogels as compared to their inactive control peptides, indicating 
that integrin activation and binding is occurring in 3-D. The nonzero values of FAK 
phosphorylation in the GAOGER and RDG control hydrogels may be due to an incomplete 
decrease in phosphorylation levels prior to seeding in the hydrogels. The low levels of cell 
growth and proliferation after encapsulation as shown by DNA content and EdU 
incorporation, combined with the high viability staining suggest that encapsulated hMSC 
are neither growing nor dying over 1 week in culture.  
We did observe an increase in ALP activity for hMSC encapsulated in ligand 
functionalized hydrogels under osteogenic stimulation, although we did not see a 
significant difference between RGD and GFOGER hydrogels. The lack of increased 
differentiation in GFOGER functionalized materials differs from previous work form our 
lab showing GFOGER enhances hMSC osteogenic differentiation [78,79,85]. It is 
important to note that the previous work with the GFOGER ligand has been on 2-D surfaces 
or porous scaffolds (2-D surfaces with curvature). Most of the differentiation protocols in 
literature are for a confluent 2-D monolayer suggesting that cell-cell contacts are crucial 
for osteogenic differentiation. Because of the nature of the 3-D microenvironment, it is 
likely that the cell density or mechanical properties used in this aim may not have been 
ideal to support osteogenesis. As previously mentioned, the aim of this project was to 
engineer an environment ultimately for cell delivery, thus finding the optimal parameters 




In this aim, we have engineered an integrin-specific cell microenvironment using 
biomimetic adhesive ligands. We have shown that we were able to control material 
properties of the matrix which were independent of ligand peptide, and that we were able 
to tune material properties such as storage modulus by varying hydrogel parameters. The 
ligand peptides exhibited specificity to expected integrins and we were able to observe 






CHAPTER 4: THE ABILITY OF INTEGRIN-SPECIFIC 
HYDROGELS TO PROMOTE HMSC SURVIVAL AND BONE 
REPAIR IN VIVO  
 
ABSTRACT 
Cell-based therapies represent promising strategies for tissue repair, although 
current cell therapies fail to address long term engraftment or delivery timing and location 
resulting in engraftment rates of less than 1%. Although bone has the innate ability to 
remodel and regenerate, large, non-healing bone defects and non-union fractures remain a 
significant clinical problem. Mesenchymal stem cell (MSC) transplantation has been 
shown to enhance bone, cartilage, and intervertebral disc repair in preclinical and clinical 
models, but engraftment rates of delivered hMSC are extremely low (<3%). The lack of 
information regarding cell fate after transplantation, cell dose, cell source, and appropriate 
scaffold properties limits the therapeutic effect of hMSC for treatment of large 
musculoskeletal defects. Integrins are a family of cell surface receptors that primarily 
mediate adhesion of cells to ECM proteins and also transduce signals across the cell 
membrane to regulate cellular activities such as migration, proliferation, survival and 
differentiation. Therefore, as a major mediator of important cellular responses, engineering 
integrin binding activity within a 3D environment may improve transplanted cell survival 
and function.  
In this study, we aimed to investigate the performance of a cell-mediated 
degradable hydrogel functionalized with integrin-specific ligands in supporting the 




accomplished this by incorporating the cell-adhesive 21 integrin-specific GFOGER 
peptide, cell-adhesive v3 integrin-specific RGD peptide, or non-adhesive RDG peptide 
combined with human mesenchymal stem cells in a protease-degradable PEG-maleimide 
hydrogel and tracked cell survival through transgenic luciferase expression. We 
hypothesized that hydrogel delivery vehicles that promote cell viability in combination 
with the pro-osteogenic properties of the carrier would result in superior bone repair. We 
found that α2β1-specific GFOGER-functionalized hydrogels promote enhanced hMSC 
survival and bone repair in vivo, compared to RGD- or RDG-functionalized hydrogels, 







Cell-based therapies represent promising strategies for tissue repair, particularly in 
cases in which host cells, due to disease, age, or excessive trauma, are unable to repair the 
defect or deficiency alone, even with additional delivered therapeutics. Current cell 
therapies fail to address long term engraftment or delivery timing and location resulting in 
engraftment rates of less than 3% as the majority of delivered cells die or are washed away 
as quickly as 1 hour post transplantation [1,2]. Long term cell engraftment has been shown 
to correlate with enhanced therapeutic outcomes [5-7], and has also been shown to be 
greater in cases in which cells are delivered in an appropriate biomaterial carrier versus in 
media alone [2,8].  
Although bone has the innate ability to remodel and regenerate, large, non-healing 
bone defects and non-union fractures remain a significant clinical problem [124]. Current 
clinical treatments for large bone defects due to disease, injury or tumor resection include 
bone grafting using autografts or allografts, but these techniques exhibit high failure rates 
and limitations due to donor site morbidity and pain, tissue availability, risk of disease 
transmission and immune rejection, and reduced biologic activity or mechanical properties 
due to processing [9,125]. The protein therapeutics bone morphogenetic proteins- (BMP) 
2 and 7 exhibit success rates similar to autografts for vertebral fusions, however, currently 
used biomaterial carriers of BMP-2, such as the collagen sponge-based INFUSE®, exhibit 
serious limitations in the control over release mechanisms and kinetics. The 
supraphysological dose required for the stimulation of bone formation leads to 




[10]. Carriers with controlled release functionality may decrease the dose and cost of BMP-
2-based therapies thereby decreasing incidence of adverse side effects [46,80].  
Mesenchymal stem cell (MSC) transplantation has been shown to enhance bone, 
cartilage, and intervertebral disc repair in preclinical and clinical models [15,16], but 
engraftment rates of delivered hMSC are extremely low (<3%) [12]. The lack of 
information regarding cell fate after transplantation, cell dose, cell source, and appropriate 
scaffold properties limits the therapeutic benefits of hMSC for treatment of large 
musculoskeletal defects.  
An appropriate carrier must support the adhesion, migration, organization, and 
differentiation of the transplanted cells and host cells. These behaviors rely on an intricate 
interaction among various cues supplied by the extracellular environment which include 
insoluble molecules within the ECM such as proteins, soluble molecules such as growth 
factors, hormones, and cytokines, and cell-cell interactions. 
Integrins are a family of cell surface receptors that primarily mediate adhesion of 
cells to ECM components and also transduce signals across the cell membrane to regulate 
cellular activities such as migration, proliferation, survival and differentiation [127]. 
Therefore, as a major mediator of important cellular responses, engineering integrin 
binding activity in addition to cell-mediated degradability within a 3D environment may 
improve transplanted cell survival and function.  
In this study, we aimed to investigate the performance of a cell-mediated 
degradable matrix functionalized with integrin-specific ligands in supporting the survival 
of transplanted hMSC and tissue repair in a segmental bone defect. We incorporated the 




specific RGD peptide, or non-adhesive RDG peptide combined with hMSC in a protease-
degradable PEG-maleimide hydrogel. The effect of hMSC delivery and ligand specificity 
on tissue repair was assessed by newly formed bone volume after treatment. The effect of 
ligand on cell survival or persistence was studied through cell tracking by transgenic 
luciferase expression and in vivo imaging. Our lab has previously shown that GFOGER-
functionalized degradable hydrogels promote enhanced bone repair in a murine segmental 
defect, and when combined with low doses of rhBMP-2, fully healed the defect [80]. We 
hypothesize that hydrogel delivery vehicles that promote cell viability in combination with 








Luciferase Lentiviral Production 
Lentiviral production was performed by the Viral Vector Core in the Neuroscience 
NINDS Core Facilities at Emory University. HEK 293FT (Invitrogen) cells were 
maintained in complete medium (DMEM, 10% FBS and 1% Pen-Strep), incubated at 37 
ºC, 5% CO2 and seeded at 70-80% confluence 1 day prior to transfection. HEK cells were 
incubated with transfection mixture (500 μg pLenti-UbC-RFLuc- tdtomato (Targeting 
Systems), 250 μg pMDLg/pRRE, 125 μg pRSV-REV187 and 150 μg pVSVG in ddH2O 
with 125 mM CaCl2 and 30 mM HEPES) for 7 hr before fresh medium change. Lentivirus 
was harvested 72 hr post transfection by centrifuging the supernatant at 500xg for 5 min at 
40 ºC, followed by passage through a 0.45 μm low protein binding filter. Filtered 
supernatant was then centrifuged at 91,000xg for 2 hr at 40 ºC in a 45Ti rotor (Beckman). 
The virus pellets were re-suspended in 500 μL PBS, and after addition of 20% sucrose as 
a cushion, centrifuged at 91,000xg for 2 hr at 40 ºC in a SW 41 rotor (Beckman). The virus 
pellet was resuspended in 100 μL PBS and stored at -80 ºC. 
Lentiviral Transduction 
Transduction protocol was adapted from Lin et al [128]. Early passage hMSC (<3) 
were seeded at 60-70% confluence and allowed to attach overnight. Media was replaced 
with a small volume of complete media containing 100 µg/mL protamine sulfate or 8 
µg/mL Polybrene. Lentivirus was thawed on ice and added to the cells at MOI 5-20. Eight 
hr after initial infection, additional complete media with protamine sulfate or Polybrene 
was added to the plate, and 24 hr after initial infection, media was replaced with fresh 




tdtomato expression by flow cytometry (BD Accuri C6). A scatter plot comparing 533 nm 
and 585 nm fluorescence emission was used in order to gate out the high auto-fluorescent 
cell population found within hMSC.  
hMSCFLuc characterization 
Cell growth capacity for hMSC transduced to express luciferase (hMSCFLuc) 
compared to hMSC was measured by fold change in DNA content over 7 days. 1000 hMSC 
or hMSCFLuc were seeded into wells of a 96 well plate and cultured in growth media. At 
days 1 and 7, cells were rinsed with PBS and plates were stored at -80 ºC until analysis. 
DNA content was measured using the CyQuant kit (Thermo Fisher) according to the 
manufacturer’s instructions. Differentiation capacity for hMSCFLuc compared to hMSC 
was measured by alkaline phosphatase activity (ALP) and mineralization. hMSC were 
seeded at 10,000 cells/cm2 on tissue culture plastic and cultured in osteogenic 
differentiation medium (basal media with dexamethasone, ascorbate, mesenchymal cell 
growth supplement, L-glutamine, penicillin/streptomycin, and β-glycerophosphate, 
Lonza). After 9 days of culture in osteogenic differentiation medium, cells were lysed and 
assayed for ALP by incubating with MUP substrate. hMSC were scraped in cold 50 mM 
Tris-HCl and sonicated to lyse the cells. The total protein content for each lysate sample 
was determined using a BCA assay kit (Thermo Scientific). Samples and ALP standards 
were loaded into a 96-well plate, then incubated with 60 μg/mL MUP substrate at 37 ºC 
for 1 hr and read at 360 nm excitation/465 nm emission. ALP activity was normalized to 
sample protein content. After 21 days in induction media, luciferase expression and 
mineralization were assessed. To visualize luciferase expression after differentiation, 




Lumina II (Perkin Elmer). Mineral deposition was visualized by Alizarin red staining. Cells 
were fixed in 10% formalin, rinsed in water, incubated in 2% Alizarin red solution for 20 
min, and washed 4 times with water.  
Implant preparation 
Implant hydrogels (3 μL) were precast within 4-mm long polyimide tube sleeves 
(Microlumen) with laser machined 300 μm diameter holes to improve nutrient transport 
and cell invasion into the defect (Figure 14). All hydrogels used for in vivo studies 
contained 4.0 - 4.5% (wt/v) PEG-maleimide and 1.0 mM adhesive peptide (unless 
otherwise stated). All implant and hydrogel components were tested for endotoxin 
contamination and were confirmed to be below 0.1 EU/mL (5-fold lower than the United 
States Food and Drug Administration’s recommended 0.5 EU/mL) by Limulus Amebocyte 
Lysate colorimetric assay (Lonza). The hydrogel was prepared as previously mentioned 
and individual implant sleeves were filled. Hydrogels were allowed to cross-link and swell 
in complete media. Cell loading efficiency was quantified for sister implant samples by 
DNA content. Implants were incubated in 1 mg/mL collagenase, type I (Thermo Fisher) at 
37 °C until fully degraded. Cells were lysed by sonication and freeze-thaw cycles. Whole 
cell lysate was assayed for DNA content and cell number using a CyQuant kit according 






Figure 14. Murine radial segmental defect.  A 4 mm polyimide sleeve laser machined with 
300 μm diameter holes along its length is filled with hydrogel prior to implantation. A 2.5 
mm defect is created in the radius and the implant sleeve is slipped over the ends of the 
defect holding the hydrogel in contact with the defect ends. 
 
Radial Segmental Defect 
All animal experiments were performed with the approval of the Georgia Tech 
Animal Care and Use Committee with veterinary supervision and within the guidelines of 
the Guide for the Care and Use of Laboratory Animals. NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ 
(NSG) male mice (8–10 weeks old, Jackson Laboratories) were anesthetized under 
isoflurane, and fur was removed from both forelimbs. The right forelimb was then swabbed 
with chlorohexidine and alcohol, and a 1.5-cm incision was made in the skin. Muscle tissue 
overlying the ulna and radius were blunt dissected, and 2.5 mm defects were made in the 
right radius using a custom-built bone cutter, while leaving the ulna intact. Implants were 
placed into the defect by fitting the polyimide sleeve over the radius at the proximal and 
distal ends of the defect holding the hydrogel in contact with the defect ends (Figure 14). 
The incision was then closed with Vicryl suture. Mice were given a single dose of slow-
release buprenorphine for pain relief and were monitored post-surgery for signs of distress, 




Cell tracking in vivo 
Bioluminescence of transplanted hMSCFLuc was measured using an IVIS Spectrum 
CT (Perkin Elmer). Luciferin salt (Promega) was dissolved in physiological saline and 
sterile filtered through 0.22 μm pore membranes. Mice received a 150 mg/kg luciferin dose 
injected into the intraperitoneal cavity. Time to maximum signal intensity was determined 
for each time point and 2D bioluminescence images were acquired 20-45 min post injection 
and analyzed with Living Image software (Perkin Elmer). Background bioluminescence of 
the unoperated arm was subtracted from the signal in the defect and signal is reported as 
photon flux which normalizes for acquisition settings and ROI area.  
Faxitron and live animal µCT 
X-ray images and 3D µCT images were acquired as previously described [80]. 
Briefly, radial defects were imaged with the MX-20 Radiography System (Faxitron). For 
µCT scanning, a 3.2 mm length of the radius centered about the 2.5 mm radial defects was 
scanned in anesthetized, live subjects using a VivaCT system (Scanco Medical, 145 mA 
intensity, 55 kVp energy, 200 ms integration time, and 15 µm resolution). Bone formation 
was evaluated by contouring 2D slices to include only the radius and applying a Gaussian 
filter. 3D µCT reconstructions display the full 3.2 mm length of radius scanned. However, 
in order to ensure that only new bone formation was measured, quantification of bone 
volume and mineral density within the defect was performed by evaluating only the middle 






Figure 15. Representative 3-D microCT reconstruction of segmental defect at day 3. 
Dashed lines show schematic of bone volume quantification.   
 
Histology and Immunostaining 
Animals were euthanized 8 weeks after surgery by CO2 inhalation and their radii 
and ulna were harvested. Soft tissue was removed carefully without disturbing the defect 
and the bones fixed in 10% neutral buffered formalin overnight. Samples were briefly 
rinsed in tap water and decalcified in formic acid for two days. The samples were processed 
for paraffin embedding and sectioned to a 5 μm thickness. For histological staining, 
sections were deparaffinized and hydrated. Sections were then stained with Weigert’s Iron 
Hematoxylin, 0.02% Fast Green, and 1.0% Safranin-O. For human-specific staining, 
sections were deparaffinized and hydrated and treated with sodium citrate buffer, pH 6.0, 
at 60 °C overnight for antigen retrieval. Endogenous peroxidase was inhibited with 3% 
H2O2 followed by blocking with 2.5% horse serum for 1 hr at room temperature (Vector 
Labs). Sections were stained with human-specific anti-NuMa (Rabbit-anti-NuMa, Abcam, 
1:100) or Rabbit IgG isotype control (1 µg/mL, Vector Labs) at 4 °C overnight, followed 
by ImmPRESS™ HRP Anti-Rabbit IgG (Vector labs) for 1 hour at room temperature. The 








 Red firefly luciferase catalyzes the oxidation of ᴅ-luciferin releasing a photon of 
light at 610 nm as a byproduct (Figure 16A). The emitted bioluminescence can then be 
detected using a charge-coupled device camera such as the IVIS. hMSC were transduced 
with a lentivirus carrying the red firefly luciferase and tdtomato genes under the ubiquitin 
C promoter (Figure 16B). Because ubiquitin C is constitutively expressed, red firefly 
luciferase and tdtomato are both stably, constitutively expressed in transduced hMSC, 
rendering bioluminescence after addition of the substrate ᴅ-luciferin a reliable marker of 
cell live cell presence. In addition, the signal intensity is proportional to cell number. 
 
 
Figure 16. Schematic of luciferase reaction for bioluminescent cell tracking.   A) In the 
presence of ATP and oxygen, firefly luciferase catalyzes the oxidation of ᴅ-luciferin 
releasing a photon of light as a byproduct. B) A plasmid carrying red firefly luciferase and 
tdtomato coexpressed under the ubiquitin C promoter is packaged into lentivirus particles 




We first examined the effect of lentiviral transduction and luciferase/tdtomato 




hMSC and assessed transduction efficiency by expression of the fluorescent protein 
tdtomato and flow cytometry. Positive hMSC were gated comparing 533 nm and 585 nm 
fluorescence emission in order to gate out the high auto-fluorescent cell population found 
within hMSC. We were able to achieve high transduction efficiencies (>90%) at relatively 
low multiplicity of infection ratios (MOI=5-15, Figure 17A) when treated with protamine 
sulfate or Polybrene. Cell growth was examined by assessing cell number by DNA content 
over 1 week in culture for unmodified hMSC and transduced hMSCFLuc (Figure 17B). The 
fold change in cell number for hMSCFLuc treated with Polybrene was significantly lower 
than unmodified hMSC or hMSCFLuc treated with protamine sulfate. To examine whether 
lentiviral transduction affected osteoblastic differentiation, hMSC and hMSCFLuc were 
grown in osteogenic differentiation medium with hMSC in growth media as a negative 
control. After 9 days in culture, ALP, an early marker of osteogenic differentiation, was 
assessed and showed no significant difference between hMSC and hMSCFLuc treated with 
protamine sulfate, whereas hMSCFLuc treated with Polybrene resulted in significantly lower 
ALP levels compared to unmodified hMSC (Figure 17C). After 21 days of osteogenic 
induction, cells were stained with Alizarin red for visualization of mineral deposits (Figure 
17D, top). To visualize luciferase expression after differentiation, luciferin was added to 
the culture medium and bioluminescence images were acquired (Figure 17D, bottom). The 
bioluminescent signal distribution correlated to the areas of high Alizarin red staining 
likely due to higher cell densities in areas of higher mineral density. We found no 
significant differences in cell functions such as growth or osteogenic differentiation 
between hMSC and hMSCFLuc when treated with protamine sulfate to increase transduction 




Polybrene treatment during transduction resulted in significantly decreased levels of 
growth and differentiation of hMSCFLuc, in agreement with previous reports [19], thus 
protamine sulfate was used in all subsequent transductions.   
 
 
Figure 17. hMSCFLuc exhibit normal growth and differentiation capacities. A) hMSC were 
transduced at high efficiency (>90%) with a lentivirus to co-express red firefly luciferase 
and tdtomato under the ubiquitin C promoter. B) Fold change in cell number by DNA 
content over 1 week for unmodified hMSC or hMSCFLuc treated with protamine sulfate 
(PS) or Polybrene (PB). hMSC and hMSCFLuc treated with protamine sulfate exhibited 
similar differentiation capacities as shown by C) ALP activity and D) mineral deposition 
by Alizarin red staining (top panel) in response to osteogenic stimulation and hMSCFLuc 
continued to express luciferase after differentiation (bottom panel). (Whiskers represent 
min and max, box extends from 25th to 75th percentiles, line represents median. N=3-4; 






We next compared hMSCFLuc to unmodified hMSC in their effect on bone repair 
after transplantation. The radial segmental defect surgery was performed as previously 
described [80]. Hydrogels for cell delivery were cast prior to surgery within a polyimide 
sleeve laser machined with holes to better support nutrient transport (Figure 14). 
Polyimide, a polymer used in FDA-approved devices, is currently used for applications 
such as encapsulation and insulation of active electrodes and retention sheaths for stents. 
The sleeve diameter is slightly larger than the diameter of the radius and is not fastened to 
the bone in any way, thus providing minimal mechanical fixation to the defect which is 
mainly stabilized by the intact ulna. The sleeve prevents the hydrogel from moving out of 
the defect space after wound closure and holds the hydrogel in contact with the defect ends. 
15,000 hMSC or hMSCFLuc were delivered to the radial segmental defect in 4.5% PEG 
(w/v) hydrogels functionalized with 1.0 mM GFOGER. Newly formed bone volume was 
measured at weeks 4 and 8. No significant differences in bone volume were found between 
hMSC modified to express luciferase and unmodified hMSC (Figure 18). The in vitro and 
in vivo results comparing hMSC and hMSCFLuc taken together show no significant 






Figure 18. Effect of genetically modified hMSC on bone repair.  Bone volume at weeks 4 
and 8 after 15,000 hMSC or hMSCFLuc delivery to the radial segmental defect in 4.5% PEG 
with 1.0 mM GFOGER hydrogels. (Whiskers represent min and max, box extends from 




Optimization of hydrogel formulation for subsequent bone repair studies 
We next tested multiple hydrogel and cell dosing parameters to optimize the 
treatment formulation for cell delivery. To investigate the effect of hydrogel polymer 
weight percent on healing, 4.5%, 6.0%, or 8.0% PEG (w/v) hydrogels with 1.0 mM 
GFOGER and 15,000 hMSC were delivered to the radial segmental defect. Representative 
3-D reconstructions are shown in Figure 19A of full 3.2 mm scans surrounding the original 
2.5 mm defect at weeks 4 and 8. The extent of defect closure increased with decreasing 
weight percent as significantly higher bone volume was measured in the 4.5% PEG-treated 
defects compared to 6% or 8%, identifying 4.5% as a suitable polymer weight percent for 






Figure 19. Effect of PEG weight percent and hMSC delivery on bone repair.  A) 
Representative 3-D reconstructions and B) bone volume of defects treated with 4.5%, 6%, 
or 8% PEG w/v with 1.0 mM GFOGER and 15,000 hMSC. (Whiskers represent min and 
max, box extends from 25th to 75th percentiles, line represents median. N=5; 2-way 




To investigate the effect of cell dose on cell survival and healing, two doses of 
hMSCFLuc, 15,000 or 30,000 per implant, were delivered to the radial segmental defect in 
4.5% PEG (w/v) hydrogels functionalized with 0.3 mM GFOGER. Bioluminescent 
tracking showed a higher signal for the 30k cell dose, as expected (Figure 20A), but the 
signals for both doses followed a similar trend over the 8 week study increasing to week 4 
and then declining gradually through week 8. When the bioluminescent signal was 
normalized to day 0 for each defect, there was no statistical difference in bioluminescence 
between the two cell doses (Figure 20B). Bone volume was measured by microCT at 
weeks 4 and 8 and showed no significant difference between 15,000 or 30,000 hMSCFLuc 
doses at either time point (Figure 21). Because we see no significant difference in bone 
volume between cell doses of 15,000 or 30,000, we chose a cell dose of 15,000 for 





Figure 20. Effect of cell dose on cell survival.  A) Bioluminescence after dose of 30,000 
or 15,000 hMSCFLuc delivered to the radial segmental defect in 4.5% PEG with 0.3 mM 
GFOGER hydrogels. B) Normalized bioluminescence to day 0 signals. (Bars represent 





Figure 21. Effect of cell dose on bone repair.  A) Representative 3-D reconstructions and 
B) bone volume at weeks 4 and 8 after delivery of 30,000 or 15,000 hMSCFLuc to the radial 
segmental defect in 4.5% PEG with 0.3 mM GFOGER hydrogels. (Whiskers represent min 
and max, box extends from 25th to 75th percentiles, line represents median. N=7; Repeated 
measures ANOVA: no differences). 
 
 
Finally, we examined the effect of ligand density in cell-free hydrogels on bone 
repair. Radial segmental defects were treated with 4.5% (w/v) hydrogels functionalized 




at weeks 4 and 8 (Figure 22). Significantly more bone was observed in defects treated with 
1.0 mM GFOGER hydrogels. However, this effect cannot be simply attributed to higher 
ligand density. Because the coupling of ligand density and cross-link density in the present 
formulations, the increased healing could be due to lower cross-link density (and therefore 
faster degradation) of the 1.0 mM ligand hydrogels. Nevertheless, these pilot studies have 
identified a promising formulation (4.5% PEG (w/v) with 1.0 mM ligand and 15,000 




Figure 22. Effect of ligand density on bone repair.  Bone volume at weeks 4 and 8 after 
radial segmental defect treatment with 4.5% PEG hydrogels functionalized with 0.3 mM 
or 1.0 mM GFOGER without cells. (Whiskers represent min and max, box extends from 







Effects of integrin-specific ligands on hMSC survival 
To assess cell number loading in hydrogel implants, cell-laden hydrogel implants 
were degraded and DNA content was measured against a cell standard curve. Figure 23A 
shows cell number for hydrogel implants functionalized with GFOGER, RGD, or RDG. 
Each implant contained an average of 15,000 hMSC with no significant differences among 
hydrogel formulations. Integrin-specific hydrogels loaded with 15,000 early passage 
hMSCFLuc were delivered into the radial segmental defect of male, NSG mice. 
Bioluminescence of transplanted hMSC was measured at multiple time points, as shown in 
Figure 23B. The bioluminescent signal for all groups increased 15-fold by week 2 and 
gradually declined through week 8. While all three groups exhibit similar bioluminescence 
trends through week 2, GFOGER maintained significantly higher bioluminescence 
between weeks 2 and 8, particularly at weeks 3, 4, and 6, while there were no significant 





Figure 23. α2β1-specific GFOGER hydrogel enhances hMSC survival.  A) DNA content 
of pre-loaded implants shows about 15,000 cells per implant and no differences among 
groups. (Whiskers represent min and max, box extends from 25th to 75th percentiles, line 
represents median. N=6 for 3 independent experiments; ANOVA: no differences). B) 




represent SEM; N=8; 2-way ANOVA: #p<0.05 GFOGER compared to RGD and RDG, 
$p<0.05 GFOGER compared to RDG).  
 
Effect of integrin-specific ligands and hMSC on bone repair 
Integrin-specific hydrogels with and without 15,000 early passage hMSC were 
delivered into the radial segmental defect of mice. Newly formed bone volume was 
monitored with live animal microcomputer tomography at weeks 4 and 8. Figure 15 shows 
a representative micro-CT reconstruction of the segmental defect at day 3. Figure 24A 
presents representative 3-D reconstructions of the full 3.2 mm scan of the original 2.5 mm 
defect plus surrounding bone and sagittal cross-sections with a mineral density heat map 
overlay. Higher amounts of bone are visualized in the 3-D reconstructions for the GFOGER 
with hMSC group, whereas all other groups exhibited low levels of bone within the defect. 
Newly formed bone volume was quantified for the middle 2.0 mm of the 2.5 mm defect to 
avoid including bone from the defect ends.  Defects treated with RGD or RDG exhibited 
very low levels of bone, with no significant difference between hydrogels containing 
hMSC and cell-free scaffolds (Figure 24). Defects treated with GFOGER-functionalized 
hydrogels without cells also exhibited low levels of bone volume, equivalent to levels in 
RGD and RDG groups, however, defects receiving hMSC in GFOGER-functionalized 






Figure 24. hMSC and α2β1-specific GFOGER enhance bone repair.  GFOGER, RGD, or 
RDG-functionalized hydrogels with or without 15k encapsulated hMSC were implanted 
into the radial segmental defect in 8-10 week old male NSG mice and bone formation was 
monitored with micro-CT. B) Representative 3-D reconstructions of 3.2 mm bone section 
surrounding original 2.5 mm defect with sagittal mineral density heat maps. Bone volume 
was quantified in the middle 2.0 mm of the original 2.5 mm defect. GFOGER + hMSC 
resulted in significantly more bone formation compared to RGD + hMSC and RDG + 
hMSC at C) week 4 and D) week 8. (Whiskers represent 10th and 90th percentiles, box 
extends from 25th to 75th percentiles, line represents median. N=13-26; Kruskal-Wallis: 




Histological sections of defects at week 8 were stained with Safranin-O/fast green 
to visualize histology of repaired bone (Figure 25). Bone marrow and lamellar bone can 




lamellar bone at the proximal and distal ends of the defect compared to RGD- and RDG-
hydrogel treated defects with and without hMSC which show pockets lacking tissue 
attributed to un-degraded hydrogel. Defects treated with GFOGER-hydrogel without 
hMSC show more collagen rich matrix in the middle of the defect compared to RGD and 
RDG-treated defects, although un-degraded hydrogel is still observed. GFOGER and 
hMSC treated defects show the most bone-like histology compared to all other conditions 
with collage-rich unorganized bone matrix in the middle of the defect. Human-specific 
nuclear mitotic apparatus (NuMa) staining confirms the presence of human cells in the 
defect at weeks 4 and 8 (Figure 26). Increased positive staining can be seen in the 
GFOGER-treated defects compared to RGD or RDG, consistent with bioluminescence 
data. The majority of stained human cells seemed to be localized in the bone marrow, 





Figure 25. hMSC and α2β1-specific GFOGER result in improved tissue of repaired bone. 








Figure 26. Human cells detected in defect by immunostaining. Human-specific NuMa 
stain (dark brown, black arrows) localizes in the nucleus and confirms presence of human 
cells in defect space of hMSC-treated defects at weeks 4 and 8. Staining with isotype 





In this study, we aimed to investigate the performance of a novel, cell-mediated 
degradable matrix functionalized with integrin-specific ligands in supporting the survival 
of transplanted hMSC and tissue repair in a segmental bone defect. We incorporated the 
adhesive 21 integrin-specific GFOGER ligand, adhesive v3 integrin-specific RGD 
ligand, non-adhesive RDG peptide combined with hMSC in a protease-degradable PEG-
maleimide hydrogel and tracked cell survival through transgenic luciferase expression. Our 
lab has previously shown that GFOGER-functionalized degradable hydrogels promote 
enhanced bone repair in a murine segmental defect, and when combined with low doses of 
rhBMP-2, fully healed the defect. We hypothesized that hydrogel delivery vehicles that 
promote cell viability in combination with the pro-osteogenic properties of the carrier 
would result in superior bone repair. 
To track cell survival in vivo, we used transgenic expression of the luciferase gene 
which relies on the photonic byproduct of the reaction between luciferase and its substrate, 
luciferin. As luciferase is an enzyme, it can only be expressed by living cells, providing an 
advantage over quantum dot or nanoparticle based tracking which may confound results if 
materials are phagocytosed by other cell types [129]. Because there is no need for an 
excitation source, unlike fluorescence-based modalities, there is very little background 
allowing for sensitive measurements. Although bioluminescence exhibits many 
advantages, there are still limitations to this method. Stable, transgenic expression of the 
luciferase gene must be maintained, in our case by means of lentiviral transduction, which 
may have downstream effects due to genome insertion location or residual viral protein 




of the appropriate substrate, usually through a systemic injection into the intraperitoneal 
cavity, the kinetics of the substrate movement, first, to the defect site, and second, into the 
implant material to the transplanted cells, must be determined for each model. As with all 
cell tracking modalities, though, the signal must be validated as representative of actual 
cell number due to other possible confounding factors. We found no significant differences 
between hMSC and hMSCFLuc with respect to in vitro cell function or in vivo bone repair. 
In vitro, hMSCFLuc demonstrated equivalent levels of cell growth and osteogenic 
differentiation to unmodified hMSC. When both cell types were delivered to the mouse 
radial segmental defect, equivalent amounts of bone were observed in the defect, therefore 
luciferase expression did not affect in vivo bone repair.  
The murine radial segmental defect provides many significant advantages over 
other bone defects – stabilization by the ulna eliminates the need for fixation hardware and 
the small model allows for in vivo imaging techniques such as bioluminescence or 
transgenic strains. However, the defect is not without its limitations – an unknown 
contribution from the ulna due to its close proximity, the small size of the defect does not 
present the same vascularization or diffusion challenges as larger defects, and the use of 
immunodeficient mice in our studies is not representative of a clinical therapy. 
Nevertheless, the relatively simple procedure (compared to more complex defects such as 
the cranial defect or femoral defect) lends itself as a useful screening model to identify 
candidate conditions for larger, more challenging injury models.  
To identify an appropriate treatment formulation for subsequent studies on the 
effect of ligand on hMSC survival and bone repair, we first examined the effect of various 




density on bone repair. We hypothesized that lower weight percent hydrogels would 
support better tissue repair due to lower cross-linking density, thereby allowing for faster 
tissue ingrowth. When we varied polymer weight percent from 4.5% to 8.0% (w/v) while 
holding ligand density and cell dose constant, we observed higher bone volumes in 4.5% 
hydrogels with lower bone volumes in 6% hydrogels and very little healing in 8.0% 
hydrogels, supporting our hypothesis that lower weight percent hydrogels, and therefore 
hydrogels with lower cross-linking densities, support increased tissue growth. For hydrogel 
systems, like the one employed in this study, in which degradation is primarily mediated 
by enzyme-degradable cross-linkers, there are three main strategies in which degradation 
can be tuned: 1. varying macromer molecular weight [32], 2. varying polymer weight 
percent [41,42], and 3. choice of cross-linker in terms of degradability [130]. Our lab and 
others have shown significantly increased tissue ingrowth and bone repair when MMP 
sensitivity is engineered into synthetic matrices compared to MMP insensitive matrices, 
confirming that matrix degradation is required for improved tissue ingrowth [32,50,80]. 
Lutolf et al. compared synthetic matrices of varying macromer molecular weights but 
equivalent polymer weight percentages in a calvarial defect. They found improved bone 
repair in defects treated with synthetic matrices of higher molecular weight and thus, lower 
cross-link density showing that tissue infiltration is greatly increased with lower cross-link 
densities [32]. In our hands, we observed the same trend, in which 4.5% hydrogels, with 
the lowest cross-linking density, exhibited greater tissue ingrowth compared to 6.0% and 
8.0% hydrogels of higher cross-link densities. Although increasing matrix degradability by 
decreasing cross-link density supports better tissue repair, there is likely a balance between 




providing cell instructive cues and mechanical support. For example, a material that 
degrades too slowly may not allow for cell infiltration and vascularization, but a material 
that degrades too quickly may not persist long enough to provide structural support or 
repair cues, or retain transplanted cells at the defect site. 
When we varied ligand density for in vivo bone repair (note that cells were not 
delivered for this study), we observed significantly more bone in defects treated with 1.0 
mM GFOGER hydrogels compared to 0.3 mM GFOGER hydrogels. Due to the coupling 
of ligand density and cross-link density in the formulations examined, the increased healing 
cannot be solely attributed to a higher adhesive peptide density. It is likely that because of 
the lower cross-link density and faster degradation of the 1.0 mM ligand hydrogels, as more 
maleimides were conjugated to ligand and less were available for cross-linking in the 1.0 
mM GFOGER hydrogels compared to the 0.3 mM GFOGER hydrogels, better bone repair 
was obtained. A more controlled experiment to decouple ligand density and cross-linking 
density is to use an inactive, mutated peptide, such as GAOGER, at varying ratios with the 
active peptide GFOGER, such that equal numbers of maleimides are reacted with ligand 
peptides resulting in equal number of maleimides remaining for cross-linking for hydrogels 
of varying active peptide density. Our lab has previously performed such an experiment to 
test the effect of RGD density on epithelial morphogenesis [44].  
One of the limitations of the size of the radial defect and the method in which cells 
are encapsulated in the hydrogel is the number of cells that we were able to incorporate 
while maintaining hydrogel integrity. The two cell doses examined in this study, 30,000 
and 15,000 (corresponding to about 15 x 106 and 7.5 x 106 cells/mL) per hydrogel, represent 




cell dose, respectively. We found no significant differences between the two cell doses in 
terms of normalized bioluminescent signal or bone repair. Thus, to decrease the number of 
cells needed, we chose to use the lower cell dose in subsequent studies. There is likely a 
balance between delivering enough cells to have a significant effect and delivering too 
many cells leading to adverse effects such as high competition for limited nutrients (with 
other transplanted cell or host cells) and significant cell death. The effective cell dose also 
depends on the efficacy of the delivery strategy in supporting and maintaining cell viability 
after transplantation. Other groups that have delivered cells to the murine radial defect have 
delivered 1 x 106 – 3 x 106 cells on collagen scaffolds per defect, although the number of 
actual cells seeded on scaffolds and implanted into the defect was not quantified [71,131-
135]. Interestingly, when BMP-2 overexpressing mouse MSC were delivered to the mouse 
radial segmental defect on a collagen sponge, a significant increase in bone formation was 
observed compared to control MSC [71]. Because cell survival and released BMP-2 
amounts were not studied, it is unknown if the increase in bone formation (including large 
amounts of ectopic bone) was due to sustained release of BMP-2 over the course of healing 
or an initial, burst release of BMP-2 followed by significant cell death. The latter scenario 
may explain the very low amounts of healing and bone formation observed in the control 
MSC group on collagen scaffolds. A range of cell doses are reported in literature for other 
bone defects such as 1-3x106 cells in a rat femoral defect [129,136], 5x104 – 2.5x106 cells 
in a mouse calvarial defect [51,137], 2x105 cells in a mouse femoral defect [67], 1x106 rat 
MSC in a rat femoral fracture [138],  and 1.5x106 cells in a rat cranial defect [139]. 
When we implanted hMSCFLuc in ligand-functionalized hydrogels, we found that 




increased after injury in all conditions, but GFOGER-treated defects exhibited significantly 
enhanced bioluminescence at later time points compared to RGD- and RDG-treated 
defects, suggesting an effect of integrin-specificity on cell survival. Interestingly, 
bioluminescence was still detectable above background at 8 weeks for all conditions, which 
represents a significant improvement over reports in the literature which document 
complete loss of signal by this time point [51,101,137,138,140-142]. We also found that 
the kinetics of injected luciferin distribution to the defect and time to maximum signal 
varied with time point, with shorter times to maximum signal at later time points and longer 
times to maximum at early time points, but no significance among groups (Figure 43).  We 
also did not find a correlation between hMSC dose or bioluminescent signal and bone 
formation. Olivo et al reported a very strong, positive correlation (r2=0.98) between hMSC 
seeding density on porous biphasic calcium phosphate scaffolds and bone deposition, 
however, their report studied ectopic bone formation in a subcutaneous pocket – a 
significantly different injury environment compared to the orthotopic radial defect model 
[140].  
Bone repair after radial defect treatment with cell-free GFOGER, RGD, or RDG 
functionalized hydrogels was minimal and not significantly different among ligands. Bone 
volumes were equally low at weeks 4 and 8 with low levels of bone ingrowth into the defect 
space as visualized by microCT and histological staining. Bone volumes in cell-free 
GFOGER hydrogels were lower than previously observed in our lab [80], but mouse strain 
and hydrogel formulation have been changed for our study to better support cell 
encapsulation, thus bone volume results may not be directly comparable. Defects treated 




significant difference between hydrogels containing hMSC and cell-free scaffolds. 
However, defects receiving hMSC in GFOGER-functionalized hydrogels resulted in 
significantly higher levels of bone formation at weeks 4 and 8 and improved morphology 
as visualized by histological staining. The significantly enhanced hMSC survival and bone 
repair observed in GFOGER-functionalized hydrogels suggest that integrin-specificity 
may be a novel strategy for enhancing tissue repair and transplanted cell survival.  
Many groups have delivered MSC or bone marrow stromal cells for bone repair 
and have reported mixed therapeutic benefits of cell delivery. The use of an appropriate 
scaffold is necessary not only to provide the correct cues to transplanted and host cells, but 
to also retain cells at the site of injury. When Kodama et al injected a suspension of rat 
MSC to a rat femoral fracture, they observed little effect of cell delivery on bone repair, 
however, when an external magnetic targeting system was used to retain cells at the defect 
site, there was a moderate effect on bone repair [138]. Several groups have reported no 
effect of transplanted cells on various scaffolds on bone repair and required additional 
growth factors or genetic modifications for a significant effect. Degano et al reported no 
effect of hMSC compared to the cell-free RGD-PEG-vinylsulfone hydrogel scaffold in a 
mouse calvarial defect [51]. Watson et al also observed no effect of rat MSC in a rat cranial 
defect compared to cell-free methacrylated thermogelling hydrogels [139]. Vila et al found 
no significant differences in bone repair in a mouse calvarial defect for hMSC on a fibrin-
BMP-2-PGDF-BB scaffold compared to the cell-free scaffold and untreated control [137]. 
Kanczler et al reported no effect of human bone marrow stromal cells on a poly(lactic acid) 
scaffold in a mouse femoral defect, and required the addition of VEGF for increased repair 




treatment with rat bone marrow stromal cells in a RGD-alginate scaffold in a rat femoral 
segmental defect and required exogenous BMP-2 for a significant effect of cell delivery 
[136]. When 2x106 mouse MSC were delivered to the mouse radial defect on a collagen 
sponge (100x more cells than used in our studies in the same defect), minimal bone 
formation was observed, possibly due to an inappropriate cell dose or rapid cell death – 
neither of which were directly assessed [71]. However, when Dupont et al delivered hMSC 
or human amniotic fluid stem cells on a GFOGER and collagen I-coated polycaprolactone 
scaffold, they observed a significant effect of cell delivery on bone repair compared to the 
cell-free scaffold [129]. The mixed reports of therapeutic benefit of cells and scaffold 
delivery on bone repair in addition to the results we have reported here highlight the 
importance of the use of an appropriate scaffold to study the effect of cell delivery on bone 
repair. Our results are in agreement with the results from Degano and Dosier above in that 
we observed no significant benefit of hMSC delivery when hMSC were delivered in a 
RGD- or RDG- functionalized hydrogel. However, when delivered in an appropriate 
scaffold (GFOGER-functionalized hydrogel), we not only see enhanced cell survival, but 
a significant effect on bone repair compared to the cell-free scaffold.  
Although we observed significant differences among ligands in bone repair and 
hMSC survival, it is important to consider the limitations of our study. The 
immunocompromised NSG mouse used in these studies was necessary to assess the effect 
of ligand on human cell survival after transplantation and the effect of hMSC on bone 
repair while avoiding massive xenograft rejection. The alternative, delivering mouse cells 
to an immunocompetent mouse limits the translational potential of this therapy, as 




transformations and in the profiles of effector molecules needed for immunomodulation 
[143]. NSG mice lack mature T cells, B cells, or functional NK cells, and are deficient in 
cytokine signaling, thus the response that we have observed may be different from a fully 
competent host. The recent development of humanized mouse models which carry 
functional, completely engrafted human immune systems, may be a more relevant and 
useful model for studying the survival of transplanted human cells in a murine model [144]. 
The murine radial bone defect, while a useful tool for screening a number of parameters, 
does not present the same hurdles that a larger, more challenging defect presents, however, 
the small, simple animal model allowed for bioluminescent imaging and eliminated the 
need for external fixation hardware (reducing risk of infection and surgical complexity). 
Due to the size difference of 12 kDa GFOGER and 600 Da RGD, it is important to rule out 
the mere presence of the peptide or differences in the resulting hydrogel local structure as 
a contributing factor to the differences observed in cell survival and bone repair. Although 
we have included RDG as an inactive, non-adhesive control in these studies, we will 
examine the inactive, mutated GAOGER peptide in future in vivo studies as a better control 
for GFOGER. In this aim, we have engineered a novel PEG-mal cell delivery hydrogel 
system that supports hMSC survival through 8 weeks and bone repair and established a 
bioluminescent cell-tracking system. We have shown that integrin specificity may have an 
effect on transplanted cell survival, in addition to tissue-specific repair that our lab has 
previously shown [80]. Within the parameters that we studied, we observed that α2β1-
specific GFOGER supports enhanced hMSC survival and bone repair in vivo, suggesting 






CHAPTER 5: THE EFFECT OF INTEGRIN-SPECIFIC 




Mesenchymal stem cells (MSC) have emerged as a promising cell source for 
regenerative medicine applications for musculoskeletal deficiencies and exhibit 
immunosuppressive properties in response to allogeneic immune responses and anti-
inflammatory effects after activation with pro-inflammatory cytokines. Recent work has 
shown that MSC can actively interact with components of the immune system and display 
both anti-inflammatory and pro-inflammatory effects.  
In this study, we aimed to gain more insights into the differential effects of adhesive 
peptide ligand in PEG hydrogels and hMSC delivery on the in vivo bone repair 
environment. First, we analyzed gene expression in vivo to investigate which genes were 
regulated after hMSC delivery and whether adhesive peptide influenced that profile. We 
then investigated whether adhesive ligand has an effect on the cytokine secretome of 
encapsulated hMSC in vitro, with and without exogenous pro-inflammatory stimulation. 
We found significant differences in gene expression in vivo after transplantation of hMSC 
in GFOGER, RGD, or RDG hydrogels. We also found that GFOGER-functionalization 
resulted in significant differences in the secreted cytokines of encapsulated hMSC 










Mesenchymal stem cells (MSC) have emerged as a promising cell source for 
regenerative medicine applications for musculoskeletal deficiencies [11,12]. In addition to 
their differentiation potential, hMSC have been reported to also provide anti-apoptosis, 
angiogenesis [17], growth factor production [18], neuroprotection [19], anti-fibrosis [2,20], 
and chemo-attraction functions [21]. They also exhibit immunosuppressive properties in 
response to allogeneic immune responses [22,23] and anti-inflammatory effects after 
activation with pro-inflammatory cytokines [24,25] secreted by inflammatory cells or 
through exogenous stimulation in culture. Recent work has shown that MSC can actively 
interact with components of the immune system and display both anti-inflammatory and 
pro-inflammatory effects [143]. MSC have the ability to interact with T cells, B cells, 
natural killer cells and dendritic cells [145] and to adopt a phenotype in response to the 
inflammatory environment which can then skew macrophage polarization [146]. 
Bone healing following injuries resulting in gaps larger than 0.5 mm involves 
overlapping phases of inflammation, renewal, and remodeling [147]. An initial 
inflammatory response is activated directly after injury initiating a well-orchestrated 
cascade of inflammatory mediators to recruit inflammatory cells and promote angiogenesis 
[148]. Activated platelets and osteoprogenitor cells release growth factors to recruit and 
guide endogenous MSC, and this phase is usually completed by the end of the first week 
[147]. A renewal phase follows in which chondrogenesis occurs forming a cartilaginous 
callus which is then mineralized into woven bone through growth factor signaling [147]. 




inflammatory signals to direct osteoblast and osteoclast differentiation and renewal and 
resorption of woven bone into lamellar bone [148]. 
In this study, we aimed to gain more insights into the differential effects of hydrogel 
adhesive peptide and hMSC delivery on the repair environment. First, we analyzed gene 
expression in vivo to investigate which genes were regulated after hMSC delivery and 
whether adhesive peptide ligand influenced that profile. We then investigated whether 
adhesive ligand has an effect on the cytokine secretome of encapsulated hMSC in vitro, 






RNA isolation and cDNA purification 
Radial segmental defects in 8-10 week old male NSG mice (Jax) were treated with 
4.5% hydrogels functionalized with 1.0 mM GFOGER, RGD, RDG, or GAOGER and 
cross-linked with 75:25 VPM:DTT with 15k hMSC (n=7-8). The tissue within the 2.5 mm 
defect space was explanted at 1 week post-transplantation and stored in RNAlater solution 
(Qiagen) until further processing. Samples were placed in Qiazol solution (Qiagen), lysed 
by probe sonication, and homogenized in QIAshredder columns (Qiagen). Total RNA was 
isolated using an RNAeasy Plus Micro kit (Qiagen), and RNA content and purity were 
measured by spectrophotometry (NanoDrop 1000). cDNA synthesis was performed on 
total RNA (100 ng) using the High-Capacity RNA-to-cDNA Kit (Thermo Fisher).  
qPCR microarray 
Quantitative PCR was performed using Fluidigm 96×96 nanofluidic arrays 
targeting a set of 96 transcripts (human or murine) to observe changes in bone, survival, 
inflammation, vascularization, and matrix markers. The genes were pre-amplified in a 
single 13-cycle PCR reaction for each sample with EvaGreen Mastermix (Fluidigm 
BioMark) following the manufacturer’s protocol. Sixty-three gene targets resulted in 
detectable qPCR results and are listed in Table 3. All subsequent statistical analyses were 
carried out using JMP-Genomics (SAS Institute, Cary, NC, USA) using the basic gene 
expression workflow [149]. Raw Ct values were imported into JMP-Genomics and 
normalized to mean Ct values across all genes for each sample for principal components 
analysis (PCA), assessment of the biological principal variance component contributions 




expression profile. Finally, the estimate builder function in JMP-Genomics was used to 
perform analysis of variance (ANOVA) of pairwise contrasts of cluster differences with a 
false discovery rate (FDR) of 5% cutoff for inclusion in downstream analysis. Results are 
presented as raw Ct values normalized to mean Ct values across all genes for a sample. 
 Cytokine analysis in vitro 
Early passage (< 6) hMSC were encapsulated in 25 μL 4.5% hydrogels 
functionalized with 1.0 mM GFOGER, RGD, RDG, or GAOGER and cross-linked with 
75:25 VPM:DTT. Hydrogels were cultured in complete media overnight followed by 
stimulation with 50 ng/mL (1000 U/mL) recombinant human IFN-γ and 20 ng/mL (1520 
U/mL) recombinant human TNF-α (R&D Systems) or no stimulation for 48 hours. 
Conditioned medium was collected, supplemented with Halt protease inhibitor (Thermo 
Fisher), and centrifuged at 10,000xg for 10 min at 4 ºC to remove debris. Supernatant was 
frozen in liquid nitrogen and stored at -80 ºC until analysis. Conditioned media were 
analyzed using the Bio-Plex Pro Human Cytokine 27-plex Assay (Bio-Rad) on a Magpix 
multiplexing machine (Luminex) according to the manufacturer’s instructions. Multiple 
comparisons for secretion levels for each cytokine were performed using Fisher’s LSD test 
as only 3 comparisons were considered: GFOGER vs. RGD, GFOGER vs. GAOGER, and 





Table 3. Gene targets for qPCR microarray.







ANGPTL4 angiopoietin-like 4 ACTA2 actin, alpha 2, smooth muscle, aorta 
BAX BCL2-associated X protein ANGPT1 angiopoietin 1 
Bcl2 B-cell CLL/lymphoma 2 BGLAP3 
Bone gamma-carboxyglutamate 
protein 3 
BMP2 bone morphogenetic protein 2 CCL2 chemokine (C-C motif) ligand 2 
CCND1 cyclin D1 CCR2 chemokine (C-C motif) receptor 2 
CDKN1A 
cyclin-dependent kinase inhibitor 
1A CSF2 colony stimulating factor 2  
col1a2 collagen, type I, alpha 2 CX3CR1 chemokine (C-X3-C motif) receptor 1 
col3a1 collagen, type III, alpha 1 CXCL12 chemokine (C-X-C motif) ligand 12 
CXCL5 chemokine (C-X-C motif) ligand 5 CXCL15 chemokine (C-X-C motif) ligand 15 
CYGB cytoglobin CXCL2 chemokine (C-X-C motif) ligand 2 
DAPK3 death-associated protein kinase 3 EPO erythropoietin 
Dlx5 distal-less homeobox 5 FGFR1 fibroblast growth factor receptor 1 
EGF epidermal growth factor FGFR2 fibroblast growth factor receptor 2 
FGF7 fibroblast growth factor 7 FLT1 FMS-like tyrosine kinase 1 
FGFR1 fibroblast growth factor receptor 1 HGF hepatocyte growth factor 
FN1 fibronectin 1 IBSP integrin binding sialoprotein 
GPX1 glutathione peroxidase 1 IFNg interferon gamma 
HGF hepatocyte growth factor IL1a interleukin 1 alpha 
HIF1a 
hypoxia inducible factor 1, alpha 
subunit IL1b interleukin 1 beta 
IGF1 insulin-like growth factor 1  KDR kinase insert domain protein receptor 
ITGa5 integrin, alpha 5 MMP9 matrix metallopeptidase 9 
ITGav integrin, alpha V NFkB1 
nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 
1 
ITGb1 integrin, beta 1 RUNX2 runt-related transcription factor 2 
KITLG KIT ligand TNF tumor necrosis factor 
MMP1 matrix metallopeptidase 1 VEGFA vascular endothelial growth factor A 
MMP13 matrix metallopeptidase 13   
MMP14 matrix metallopeptidase 14   
MMP2 matrix metallopeptidase 2   
NES nestin   
NFkB1 
nuclear factor of kappa light 
polypeptide gene enhancer in B-
cells 1   
PPARg 
peroxisome proliferator-activated 
receptor gamma   
TGFBI 
transforming growth factor, beta-
induced   
TIMP1 TIMP metallopeptidase inhibitor 1   
TIMP2 TIMP metallopeptidase inhibitor 2   
TP53 tumor protein p53   
VEGFA vascular endothelial growth factor A   
Wnt5a 
wingless-type MMTV integration 
site family, member 5A   






Effect of ligand on gene expression after hMSC delivery in vivo 
To gain more insights into the effect of adhesive peptide ligand presented in the 
delivery hydrogel on the repair environment in vivo, we first examined gene expression at 
an early time point, as others have shown differential gene expression at 1 week or earlier 
[150]. 15,000 hMSC were delivered to the murine radial segmental defect in GFOGER-, 
RGD, or RDG-functionalized hydrogels. Tissue within the defect space was explanted 1 
week after transplantation and processed for RNA extraction. We identified 96 human or 
mouse gene targets of interest that were related to vascularization, bone, inflammation, 
wound healing, matrix proteins, and cell survival (Table 3). Of the initial 96 gene targets, 
approximately 60 resulted in a detectable signal after microfluidic PCR analysis on the 
Fluidigm system. When we analyze the entire data set of detectable genes, discriminant 
analysis shows clear separation of the samples grouped together based on adhesive peptide 
(Figure 27). Discriminant analysis aims to classify observations described by values on 
continuous variables (covariates) into groups.  The canonical plot visually represents this 
analysis and shows the sample points and multivariate means in the two dimensions, or 
canonical variables, that best separate the groups. The “+” plus marker corresponds to each 
multivariate mean and ellipses represent a 95% confidence level – thus groups that differ 
significantly tend to not intersect. The canonical plot in Figure 27 shows the adhesive 
peptide groups GFOGER and RGD closer together and more removed from RDG along 
the canonical 1 axis, but with no overlap among the groups. Along canonical 2, RGD and 




groups, indicating more similarity between RGD and RDG than GFOGER and RGD or 
GFOGER and RDG. 
Hierarchical clustering based on adhesive peptide shows GFOGER samples tightly 
clustered, while RGD and RDG samples cluster together without much separation between 
the two (Figure 27). Clustering with respect to gene expression levels shows two clear 
clusters – cluster 1 solely consisting of human genes and cluster 2 primarily consisting of 
mouse genes (Figure 28). This clustering is not surprising as the different species targets 
likely exhibit different variances. From the cluster expression map, we can clearly observe 
areas of differential gene expression. We then split the genes according to cluster (cluster 
1 (human) vs. cluster 2 (mouse)), and compared ligands by multivariate ANOVA 
(MANOVA) with a sum combination across genes, essentially transforming the 
multivariate data set into a univariate data set. The MANOVA revealed significant 
differences in each cluster with respect to adhesive peptide (p<0.05), and the centroid 
canonical plot shows that while the centroids for RGD and RDG exhibit considerable 
overlap, suggesting high similarity, the centroid for GFOGER is the farthest removed with 
minimal overlap, signifying that both hMSC delivered in GFOGER hydrogels and defects 
treated with hMSC in GFOGER-functionalized hydrogels exhibit significantly different 






Figure 27. Discriminant analysis of gene expression.  Linear discriminant analysis of gene 
expression after 1 week. Each point represents a sample and each multivariate mean is a 
labeled circle corresponding to a 95% confidence limit for the mean. Groups that are 
























































































Figure 29. Defects treated with hMSC in GFOGER hydrogels exhibit differential gene 
expression profile compared to other ligands.  Multivariate ANOVA with a sum 
combination across genes for A) cluster 1 (human genes) and B) cluster 2 (mouse genes) 
indicates that hMSC encapsulated in GFOGER-functionalized hydrogels and defects 
receiving hMSC in GFOGER hydrogels exhibit significantly different gene expression 
profiles in vivo at 1 week as shown by centroid canonical plots. (N=7-8; MANOVA: 
p<0.05 for cluster 1 and cluster 2). 
 
 
Figure 30 shows genes sorted by categorical function with red indicating higher 
normalized expression and blue representing lower normalized expression. We can see 
clear differences among adhesive peptides in expression of vascularization, inflammation 
and bone related genes. Using ANOVA to detect significant differences among ligands for 
each gene, relative expression levels of genes displaying differential expression with 





Figure 30. Gene expression heat map.  hMSC transplantation in α2β1-specific GFOGER 
hydrogels resulted in upregulation of inflammation, vascularization and bone genes in vivo 
after 1 week compared to RGD and RDG. Tissue was explanted from the defect space after 
1 week and total RNA was extracted and standardized across all samples. 96 total genes 




Inflammation genes with differences among hydrogel adhesive peptides are shown 
in Figure 31. Mouse host genes tumor necrosis factor (TNF), interleukin 1-beta (IL-1β), 
stromal cell-derived factor 1 (SDF-1/CXCL12), monocyte chemoattractant protein-1 
receptor (CCR2), macrophage inflammatory protein 2-alpha (MIP-2α/CXCL2), and 
nuclear factor kappaB (NFκB) were upregulated in GFOGER- compared to RDG-
hydrogels. Interestingly, human NFκB was upregulated in RDG compared to GFOGER. 
SDF-1/CXCL12 is a chemokine for lymphocytes and endothelial progenitor cells and plays 
an important role in vascular development. Using CXCR4 knockout mice (the receptor for 
SDF-1), Kawakami et al demonstrated that SDF-1 plays an important role in bone fracture 
healing [151], and SDF-1 can be induced by both TNF and IL-1 [152]. TNF, IL-1β,  and 
MIP-2α/CXCL2, pro-inflammatory cytokines, have been shown to be upregulated during 
the early inflammation phase and then decrease to baseline levels during normal fracture 
healing and tooth extraction socket healing [153,154], however IL-1β is translated as pro-
IL-1β and must be processed by caspase-1 for biological activity [155]. MCP-1, the ligand 
for CCR2, plays a critical role in the recruitment and activation of leukocytes, including a 
subpopulation of macrophages critical for angiogenesis, and is specifically regulated 
during activation of skeletal repair and remodeling [156,157]. NFκB, a transcription factor, 
requires activation through one of two distinct pathways for translocation to the nucleus 
and can interact with over 200 genes depending on the stimuli and cell type regulating 





Figure 30 continued. …genes. Mean normalized Ct values were used for the analysis and 




mediators [159]. The inflammatory mediators upregulated in the GFOGER group are 
important in the early phase of healing and recruit inflammatory cells which promotes 
angiogenesis. Prolonged expression of these molecules may lead to abnormal healing and 
persistent inflammation, however, upregulated expression at 1 week after injury is in line 




Figure 31. Differentially expressed inflammation genes in vivo at 1 week.  (Whiskers 
represent min and max, box extends from 25th to 75th percentiles, line represents median. 




Vascularization genes showing differences among groups are shown in Figure 32. 
Mouse genes matrix metallopeptidase 9 (MMP), angiopoietin 1 (Agnpt1), VEGF receptor 
2 (VEGFR2/KDR), alpha actin 2 (ACTA2), VEGF receptor 1 (VEGFR1/FLT1), and 




RGD and RDG. Human hypoxia inducible factor 1α (HIF1a) was upregulated in RGD and 
RDG and human hepatocyte growth factor was upregulated in RDG. VEGF, the ligand for 
VEGFR2/KDR and VEGFR1/FLT1, is involved in endothelial cell migration, mitogenesis, 
sprouting, and tube formation, and upregulated VEGF and VEGFR have been detected in 
the tips of angiogenic sprouts [160]. FGF, the pro-angiogenic ligand for FGFR2, is 
upregulated during angiogenesis and is stored in the basement membrane as a reservoir 
supply. It enhances VEGF production and induces placental growth factor expression in 
the presence of VEGF, exhibiting cross talk with other growth factor pathways [161]. 
ANGPT1 functions primarily during vascular remodeling and angiogenesis to stabilize 
new blood vessels and regulate endothelial cell survival. It acts as a competitive agonist 
for ANGPT2 which is involved in the disruption of the endothelial monolayer promoting 
sprouting and angiogenesis [162]. MMP9 is critical in vascular remodeling, cell migration, 
and sprout formation as protein inhibitors of MMP9 have been shown to attenuate the 
migration of endothelial cells [160]. ACTA2 is a marker of pericytes, a cell type required 
for the maturation and stabilization of new blood vessels [163]. The HIF-1α pathway is 
activated in response to hypoxia, and overexpression has been linked to increases in 
osteogenesis and angiogenesis [60]. HGF, a paracrine factor reported to be secreted by 
apoptotic cells, stimulates endothelial cell motility and growth and activates the NFκB 
pathway which can then regulate HIF-1α expression [164,165] – interestingly, human 
HGF, NFκB, and HIF-1α were all upregulated in RDG hydrogels compared to hydrogels 
presenting adhesive peptides. Many critical angiogenic mediators were found to be 
upregulated in the host in the GFOGER group, whereas hypoxic and apoptotic markers 





Figure 32. Differentially expressed vascularization genes in vivo at 1 week.  (Whiskers 
represent min and max, box extends from 25th to 75th percentiles, line represents median. 




Figure 33 shows bone related genes with significant differences among groups. 
Runt-related transcription factor 2 (RUNX2) and bone sialoprotein (IBSP) mouse genes 
were upregulated in GFOGER hydrogels whereas human bone morphogenetic protein 2 
(BMP2) was upregulated in RGD and RDG. RUNX2 is a master transcription factor and 
regulator of bone matrix genes, including IBSP, a significant component of the bone ECM 
[166]. BMP2 initiates the bone healing cascade and is critical for osteogenic differentiation 
and chondrocyte proliferation and maturation during endochondral bone development 
[167,168]. However, RUNX2 is essential for the execution and completion of BMP2 
signaling for osteoblast differentiation [169]. Gonzalez-Gil et al reported that hypoxia 
triggered BMP2 expression in human periosteum explants, supporting the upregulation of 





Figure 33. Differentially expressed bone genes in vivo at 1 week.  (Whiskers represent min 
and max, box extends from 25th to 75th percentiles, line represents median. N=7-8; 
ANOVA: *FDR<0.05). 
 
Effect of adhesive ligand on cytokine secretion profiles of encapsulated hMSC in vitro 
hMSC were encapsulated in GFOGER-, GAOGER-, RGD-, or RDG-
functionalized hydrogels. After 24 hours in culture, encapsulated hMSC were either 
stimulated or not stimulated with rhTNF-α and rhIFN-γ to mimic the inflammatory 
environment in vivo, and cultured for another 48 hours. Conditioned media was collected 
after the 48 hour stimulation period and assayed for cytokine content. We observed a 
significant effect of stimulation on all cytokine levels across hydrogel groups, except for 






Table 4. Secreted cytokine levels of hMSC encapsulated in ligand-functionalized 
hydrogels. Encapsulated hMSC were either stimulated with TNF-α and IFN-γ or 
maintained unstimulated and conditioned medium was analyzed. Table below shows 
average cytokine level across ligands. All cytokine levels were significantly affected by 
stimulation except IL-12p70. ND: Below detection limit, * significant differences in 







Basic FGF 57.5 ± 5.3* 78.7 ± 6.1* 
Eotaxin ND 91.2 ± 15.9 
G-CSF ND 98.1 ± 7.9 
GM-CSF 24.8 ± 8.1 55.3 ± 8.6 
IFN-g 630.9 ± 280.5* - 
IL-1b 3.8 ± 0.6 20.4 ± 1.9 
IL-1ra 65.5 ± 2.8* 156.1 ± 13.3 
IL-2 7.3 ± 7.6 22.6 ± 2.5 
IL-4 2.4 ± 0.4 10 ± 1 
IL-5 ND 14.3 ± 1 
IL-6 1356.8 ± 175.2* 26790.5 ± 5416.7 
IL-7 5.5 ± 1.1 10 ± 2.4 
IL-8 12 ± 3.3* 1622.8 ± 337.2* 
IL-9 19.1 ± 3.6* 32.6 ± 2.7 
IL-10 65.4 ± 16.3 76.8 ± 16 
IL-12p70 98.2 ± 11.8 91.7 ± 11.8 
IL-13 3.1 ± 0.6 5 ± 1 
IL-15 ND 104.1 ± 6.2 
IL-17a 18.8 ± 4.4 64.8 ± 5.4 
IP-10 19.4 ± 1.5 37025.7 ± 2911.3 
MCP-1 213.3 ± 46.7* 1034.9 ± 91.7 
MIP-1a 1.7 ± 0.1 3 ± 0.2 
MIP-1b 4.5 ± 1.1 10.3 ± 1 
PDGF-bb 0.4 ± 0.4 13.8 ± 3.4 
RANTES 5.1 ± 3 3860.2 ± 1342 
TNF-a 15.8 ± 7.2 - 







When we analyze the entire data set of cytokines, discriminant analysis, as 
described previously, shows clear separation of the samples based on adhesive ligand 
(Figure 34). Separation along canonical parameter 1 resulted in cytokine profiles separated 
based on adhesive peptide with the adhesive GFOGER- and RGD-hydrogels separated 
from the inactive GAOGER- and RDG-hydrogels. Separation along canonical parameter 2 
resulted in separation between GFOGER- and GAOGER-hydrogels and between RGD- 
and RDG-hydrogels, although to a lesser degree than adhesive vs. non-adhesive groups. 
Hierarchical clustering based on adhesive ligand shows separation similar to canonical 
parameter 1 in that adhesive samples GFOGER- and RGD-hydrogels form one main 
cluster, and non-adhesive RDG- and GAOGER-hydrogels form the other (Figure 35). We 
then compared adhesive ligands by multivariate ANOVA (MANOVA) with a sum 
combination across cytokines, essentially transforming the multivariate data set into a 
univariate data set. The MANOVA revealed significant differences in cytokine secretion 
level with respect to adhesive ligand (p<0.001). The centroid canonical plot shows high 
similarity and overlap between GAOGER- and RDG-hydrogels and a slightly different 
profile for RGD-hydrogel (however not significant, Figure 36). The centroid for 
GFOGER-hydrogel is the farthest removed with minimal overlap, signifying hMSC in 
GFOGER hydrogels exhibited significantly different cytokine profiles whereas there was 







Figure 34. Discriminant analysis of cytokine secretion from encapsulated hMSC without 
IFN-γ/TNF-α stimulation.  Linear discriminant analysis of cytokine secretion of hMSC 
encapsulated in ligand-functionalized hydrogels over 2 days in growth conditions. Each 
point represents a sample and each multivariate mean is a labeled circle corresponding to 
a 95% confidence limit for the mean. Groups that are significantly different tend to have 






Figure 35. Hierarchical clustering of cytokine secretion from encapsulated hMSC without 
IFN-γ/TNF-α stimulation.  Ward’s method shows clustering between adhesive and non-
adhesive hydrogels, and further clustering by ligand for secreted cytokine levels of hMSC 





Figure 36. hMSC in GFOGER hydrogels exhibit differential secretory cytokine profile 
compared to other hydrogels without exogenous stimulation.  Multivariate ANOVA with 
a sum combination across cytokines shows hMSC encapsulated in GFOGER-
functionalized hydrogels exhibit significantly different cytokine profile under growth 




Figure 37 shows individual cytokines that exhibited significant differences among 
adhesive ligands without rhTNF-α and rhIFN-γ stimulation. Interleukin 1 receptor 
antagonist (IL-1ra) and interferon gamma (IFN-γ) were upregulated in GFOGER-
hydrogels compared to its inactive GAOGER-hydrogel control. Interleukins 8 and 9 (IL-8 
and IL-9) were upregulated in RGD-hydrogels compared to RDG gels. Basic fibroblast 
growth factor (Basic FGF/FGF2) and monocyte chemotactic protein (MCP-1) were 
upregulated in both GFOGER- and RGD-hydrogels compared to their inactive controls. 
IL-8, Interleukin 6 (IL-6) and vascular endothelial growth factor (VEGF) were all 
upregulated in GFOGER hydrogels compared to RGD- and GAOGER-hydrogel control. 




[161]. IL-1ra binds the IL-1 receptor inhibiting pro-inflammatory IL-1 signaling [155]. IL-
9 is a potent, antigen-independent growth factor for T cells and mast cells and affects many 
cell types to regulate inflammation [170]. IL-6 is constitutively expressed by hMSC and 
polarizes monocytes toward an anti-inflammatory IL-10 producing phenotype [143]. The 
major effector function of IL-8 is the recruitment and activation of neutrophils to the site 
of injury [155]. MCP-1 induces CCR2-dependent migration of monocytes, particularly a 
subset of macrophages important for vascularization [155-157]. IFN-γ is a pro-
inflammatory cytokine mainly secreted by activated T cells and macrophages and activates 
the inflammatory cascade. Duque et al reported autocrine regulation of IFN-γ in hMSC, 
which regulated cell processes such as osteoblastic differentiation [171]. In our study, IFN-
γ may have an autocrine feedback effect, regulating the cytokine secretion of encapsulated 
hMSC. It is noteworthy to mention that the interaction between IFN-γ and its receptor is 









Figure 37. Cytokines with significant secretion levels for encapsulated hMSC without 
IFN-γ/TNF-α stimulation.  Concentrations of secreted levels were significantly different 
for cytokines showed above from hMSC encapsulated in ligand-functionalized hydrogels 
in growth conditions. (Whiskers represent min and max, box extends from 25th to 75th 
percentiles, line represents median. N=4; ANOVA: *p<0.05, **p<0.005, ***p<0.0005, 




When we stimulated hMSC in ligand-functionalized hydrogels with TNF-α and 
IFN-γ, we saw a significant effect of stimulation on the secretion levels of almost all of the 
cytokines tested in the conditioned medium. Discriminant analysis shows some separation 
of samples by adhesive ligand (Figure 38). Along canonical parameter 1, GFOGER- and 




parameter 2, the GFOGER, GAOGER, and RGD groups overlap with RDG slightly 
removed. Cluster analysis shows no clear pattern with respect to adhesive ligand (Figure 
39). Multivariate ANOVA, as described previously, shows no significant effect of ligand 
on cytokine secretion profiles after stimulation with IFN-γ and TNF-α (Figure 40). Upon 
analysis of individual cytokines, no cytokines exhibited differences among adhesive 
ligand, except for basic FGF which is upregulated in RDG hydrogels after stimulation 
(Figure 41). We did not detect an effect of adhesive ligand on cytokine secretion profiles 
of hMSC encapsulated in ligand-functionalized hydrogels after stimulation with IFN-γ and 
TNF-α. This is likely due to the highly potent effects of IFN-γ and TNF-α on hMSC 




Figure 38. Discriminant analysis of cytokine secretion from encapsulated hMSC with IFN-
γ/TNF-α stimulation.  Linear discriminant analysis of cytokine secretion of hMSC 
encapsulated in ligand-functionalized hydrogels with cytokine stimulation over 2 days in 
culture. Each point represents a sample and each multivariate mean is a labeled circle 
corresponding to a 95% confidence limit for the mean. Groups that are significantly 






Figure 39. Hierarchical clustering of cytokine secretion from encapsulated hMSC with 
IFN-γ/TNF-α stimulation.  Ward’s method shows no clear clustering among ligands when 






Figure 40. Stimulation masks effect of ligand on cytokine secretion profile.  Multivariate 
ANOVA with a sum combination across cytokines shows no significant differences among 







Figure 41. Cytokines with significant secretion levels for hMSC encapsulated in ligand-
functionalized hydrogels when stimulated with TNF-α and IFN-γ.  (Whiskers represent 







In this study, we aimed to gain more insights into the differential effects of adhesive 
ligand and hMSC delivery on the repair environment. Given the significantly increased 
bone repair and hMSC survival observed in radial segmental defects after delivery of 
hMSC in GFOGER-functionalized hydrogels, we hypothesized that the early gene 
expression profile in vivo would vary among ligands. First, we analyzed gene expression 
in vivo to investigate which types of genes were regulated after hMSC delivery and whether 
adhesive ligand influenced that profile. We then investigated whether adhesive peptide 
ligand has an effect on the cytokine secretome of encapsulated hMSC in vitro. 
To investigate the gene expression profiles of bone defects treated with hMSC in 
GFOGER-, RGD-, or RDG-hydrogels, 96 genes were chosen to cover a number of 
functional areas specific to mouse or human. The wide array of genes screened is a large 
advantage to the microfluidic, high throughput PCR platform that was employed in this 
study. Multivariate analysis indicated no significant difference between hMSC/RGD and 
hMSC/RDG treated defects, however, the overall gene expression pattern in 
hMSC/GFOGER hydrogel-treated defects was statistically significant compared to RGD 
and RDG gels. Upon analysis of mRNA expression from explanted tissue, we found 
significant differences in gene expression related to inflammation, vascularization, and 
bone. All of the genes upregulated in GFOGER hydrogel-treated defects were specific to 
the host response, and many have been reported to play a significant role in the normal 
fracture healing cascade. The inflammation genes upregulated in GFOGER hydrogel-
treated group are responsible for immune cell recruitment and activation, critical in 




of vascularization genes, namely angiogenic growth factor receptors and mediators of 
vessel remodeling. The upregulation of host bone genes in hMSC/GFOGER defects 
suggests that the transplanted hMSC serve as paracrine support rather than differentiation 
into the target tissue, in agreement with recent thinking [172]. Vascularization is a vital 
component to bone development and repair [173], and due to the high amounts of cross-
talk between inflammatory and angiogenic mediators, the upregulation of inflammatory, 
angiogenic, and bone related genes in hMSC/GFOGER treated defects is consistent with 
the survival and bone repair outcomes previously described. The human genes, HGF, 
NFκB, HIF-1a, and BMP-2 were found to be upregulated in hMSC/RGD and hMSC/RDG 
compared to hMSC/GFOGER-treated defects, and may indicate a lack of vascularization 
and hypoxic and apoptotic hMSC. HGF, which has been reported to be secreted by 
apoptotic cells [165], can activate NFκB which then regulates HIF-1α [164] and BMP-2 
signaling [174,175], is one possible explanation for the pattern of genes upregulated in 
RGD and RDG gels. Our result that the delivery of hMSC in an appropriate carrier 
modulates the tissue repair environment is consistent with other reports of MSC delivery. 
Seebach et al observed higher gene expression of VEGF, IL-6, and MIP-2 in vivo after 
delivery of fibrin-encapsulated rat MSC to a femur defect compared to fibrin alone [176]. 
Swartzlander et al observed a diminished fibrous capsule when mMSC-laden hydrogels 
were implanted subcutaneously compared to cell-free scaffolds, or scaffolds containing 
osteogenically differentiated mMSC, suggesting mMSC modulation of macrophage 
activation [177].  
The murine radial segmental defect provides many significant advantages over 




the small model allows for in vivo imaging techniques such as bioluminescence or 
transgenic strains. However, the defect is not without its limitations – an unknown 
contribution from the ulna due to its close proximity, the small size of the defect does not 
present the same vascularization or diffusion challenges as larger defects, and the use of 
immunodeficient NSG mice in our studies is not representative of a clinical therapy. The 
NSG mouse lacks B cells, T cells, natural killer cells and complement, and has defective 
dendritic cells and macrophages [178,179]. The alternative model, delivering murine cells 
to a fully competent host, diminishes translational capacity of this therapy and may not 
correspond to a human cell-based therapy. Although murine and human MSC share multi-
lineage differentiation capacity, murine MSC have been shown to exhibit high 
susceptibility to malignant transformation and carry cytogenic abnormalities [180,181]. 
The recent development of humanized mouse models which carry functional, completely 
engrafted human immune systems, may be a more relevant and useful model for studying 
the immunomodulation potential of hMSC in a murine model, however, the reports of 
eventual graft versus host disease in humanized mice warrant further characterization 
[144]. Nevertheless, the relatively simple procedure (compared to more complex defects 
such as the cranial defect or femoral defect) lends itself as a useful screening model to 
identify candidate conditions for larger, more challenging injury models. 
Although we observed significant differences in gene expression patterns in vivo 
due to ligand, the complex environment and multiple factors at play make interpretations 
complicated. Thus, we aimed to investigate whether the simple presentation of various 
integrin-specific ligands could alter the secretome of encapsulated hMSC in a more 




present in vitro. Using multiplex technology, we screened 27 cytokines in the conditioned 
media of encapsulated hMSC without exogenous stimulation. Discriminant and cluster 
analysis revealed a large separation in cytokine profile based on adhesive versus non-
adhesive peptide functionalization, and a slightly smaller, but still significant, separation 
based on integrin specificity. Multivariate analysis indicated high similarity between RDG 
and GAOGER groups, a slight, but not significant, difference due to RGD gels, and a 
significant difference in cytokine profile in GFOGER hydrogels compared to RGD, RDG, 
or GAOGER hydrogels. We observed significant increases in the secretion levels of trophic 
factors, FGF and VEGF, and inflammatory mediators, IL-6, IL-8, IL-1ra, IFN-γ, and MCP-
1 in α2β1-specific GFOGER hydrogels compared to other groups. When encapsulated 
hMSC were stimulated with exogenous TNF-α and IFN-γ, no major effect of adhesive 
ligand was detected, which may be due to the high, sustained levels of inflammatory 
stimulation. hMSC have the ability to secrete a number of  immunomodulatory factors, but 
to the best of our knowledge, no one has shown that integrin-specificity can tailor the 
secretome profile, although groups have shown effects of encapsulation, aggregation, and 
material. Rustad et al reported that mMSC encapsulated in pullulan-collagen hydrogels 
secreted higher amounts of VEGF and MCP-1 compared to plated mMSC [182]. Cantu et 
al showed that hMSC encapsulated in collagen gels secreted higher levels of IL-6 compared 
to PEG-gelatin (whose main adhesive site is RGD) [183]. Seib et al and Sumanasinghe et 
al showed that mechanical stimuli such as substrate stiffness and cyclic strain, respectively, 
can alter cytokine secretion [184,185].  
Interestingly, upon comparison of in vivo gene expression and the in vitro cytokine 




effect of GFOGER peptide on immunomodulation compared to RGD or RDG ligands. 
Higher secreted levels of the growth factors FGF and VEGF were detected for hMSC in 
GFOGER hydrogels in vitro and gene transcripts for their receptors, FGFR2, 
VEGFR2/KDR and VEGFR1/FLT1, were significantly upregulated in the host mouse 
tissue in vivo. Although mouse IL-1β gene was upregulated in vivo in GFOGER defects, 
IL-1ra levels were higher from hMSC in GFOGER in vitro, suggesting modulation of the 
important balance of IL-1 and IL-1ra in tissue homeostasis [186]. MCP-1, which plays a 
critical role in the recruitment and activation of leukocytes [156,157], was more highly 
secreted from hMSC in GFOGER in vitro and gene transcripts for its receptor, CCR2, was 
also upregulated in host mouse tissue in vivo.  
Waterman et al recently proposed a paradigm for hMSC in which hMSC can be 
polarized into two homogenously acting phenotypes – MSC1, a pro-inflammatory 
phenotype, and MSC2, an anti-inflammatory phenotype, summarized in Figure 42 [187]. 
Our data, particularly the upregulation of IL-6, VEGF, FGF, and CXCL12 of hMSC 
encapsulated in GFOGER-functionalized hydrogels, is consistent with the anti-
inflammatory MSC2 phenotype which may help to polarize monocytes towards a more 
reparative macrophage. Regardless of phenotype, this study combined with the enhanced 
bone repair and transplanted hMSC survival in vivo, shows that targeting α2β1 integrin 
during hMSC encapsulation and cell delivery has a beneficial effect on the repair 











CHAPTER 6: FUTURE CONSIDERATIONS  
 
This thesis presents a significant contribution to the field of biomaterials research 
by demonstrating the novelty of an integrin-specific, protease-degradable hydrogel in cell 
delivery and tissue repair. We have demonstrated the effect of integrin-specificity on 
transplanted cell survival, bone repair, and hMSC immunomodulatory phenotype. 
In Aim 1, we engineered an integrin-specific cell microenvironment using 
biomimetic adhesive ligands. We showed that we were able to control material properties 
of the matrix independent of ligand peptide, and that material properties such as storage 
modulus can be tuned by varying hydrogel parameters. The ligand peptides exhibited 
specificity to targeted integrins and we observed differences in cell morphology in 3-D, 
while maintaining high cell viability.  
In Aim 2, we demonstrated that the novel PEG-mal cell delivery hydrogel system 
supports hMSC survival through 8 weeks and bone repair. We have shown that integrin 
specificity has an effect on transplanted cell survival, in addition to tissue-specific repair 
that our lab has previously shown [80]. We observed that α2β1-specific GFOGER supports 
enhanced hMSC survival and bone repair in vivo, suggesting a role for integrin-specificity 
in improving transplanted cell survival and tissue repair. 
In Aim 3, we gained additional insights into how integrin-specificity may be 
modulating the repair environment. First, we observed significant differences due to 
adhesive peptide in the gene expression profiles in vivo with respect to bone, inflammation, 
and vascularization. Second, we observed a significant effect of integrin-specificity on the 




of in vivo gene expression and the in vitro cytokine profile, we observed some consistent 
upregulations that support a differential effect of GFOGER on immunomodulation 
compared to RGD or RDG, specifically in growth factor signaling and immune cell 
recruitment and activation. Taken together, these observations suggest that GFOGER 
hydrogels may be polarizing hMSC toward an anti-inflammatory MSC2 phenotype, which 
may help to polarize monocytes towards a more reparative macrophage phenotype [187]. 
Regardless of phenotype, this study combined with the enhanced bone repair and 
transplanted hMSC survival in vivo, shows that targeting α2β1 integrin during hMSC 
encapsulation and cell delivery has a beneficial effect on the repair environment and overall 
repair outcomes. 
 Future studies as follow up to this thesis include studying the effect of encapsulated 
hMSC and adhesive peptide on a wider array of secreted cytokines and immunomodulatory 
factors or monocyte migration and polarization. Investigating the cytokine profile in vivo 
after hMSC delivery would shed additional light on the effects of ligand on the repair 
environment. There is also room for improvement of our cell delivery strategy as our most 
therapeutic condition, hMSC in GFOGER-functionalized hydrogels, fails to achieve full 
healing of the defects. Modifying hydrogel parameters such as macromer size and thus 
mesh size, cross-link degradation kinetics, or ligand density may have an effect on tissue 
repair. The limitations of our bone injury model such as size, ulna proximity, and the use 
of an immunocompromised host, warrants investigation of the performance of our cell 





There is growing evidence that MSC exhibit great potential beyond multipotent 
differentiation and that they actually lose their immunomodulatory properties after 
differentiation [177]. Swartzlander et al showed that delivery of encapsulated mMSC 
reduced fibrous capsule formation compared to cell free scaffolds, thus it would be 
interesting to study the effect of adhesive peptide and hMSC on fibrous capsule given the 
differences in behavior of mouse versus human MSC [143]. Immunomodulation provided 
by hMSC encapsulated in GFOGER hydrogels may also be therapeutic in tissue injury 
models such as after myocardial infarction or after islet transplantation for type 1 diabetes.  
 Ultimately, these studies provide insight into the effects of integrin-specificity on 
transplanted hMSC survival, bone repair, and hMSC immunomodulation. A novel, highly 
defined, integrin-specific hydrogel system was evaluated for cell encapsulation in vitro, as 
well as in a relevant segmental bone defect model in vivo. These studies demonstrated the 
potential of integrin-specificity, specifically, targeting the α2β1 integrin with GFOGER, in 
augmenting cell survival after transplantation, enhancing tissue repair, and modulating the 
immunomodulatory properties of hMSC. Altogether, this thesis provides integrin-








KINETICS OF TIME TO MAXIMUM SIGNAL FOR BIOLUMINESCENT 
IMAGING 
 
15,000 hMSCFLuc were delivered in ligand-functionalized hydrogels to the radial 
segmental defect. Mice received a luciferin dose of 150 mg/kg delivered intraperitoneally 
prior to imaging. At each time point, images were acquired every 2 minutes until maximum 
signal was reached to establish kinetic curves. Signal was maintained between 90%-100% 
of maximum for roughly 15 min.  
 
 


































Bone regeneration using an alpha 2 beta 1 integrin-specific hydrogel as a BMP-2 






























Microphysical space of a liver sinusoid device enables simplified long-term 
maintenance of chimeric mouse-expanded human hepatocytes. Biomedical 


































Integrin-specific hydrogels functionalized with VEGF for vascularization and bone 
regeneration of critical-size bone defects. Journal of Biomedical Materials Research 






































Human Mesenchymal Stem Cell Behavior on Segmented Polyurethanes Prepared 






































Tobacco Mosaic Virus Functionalized Alginate Hydrogel Scaffolds for Bone 
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